藥品代碼,適用族群(成人/兒童),檢驗方式,下限,上限,下限單位,上限單位,建議,備註,新增時間,修改時間
EAKL,成人,Clcr,0,999.00,mL/min,mL/min,不曾在腎功能不全的病人中對Aklief進行過研究。,[仿單],202412061109,202412061109
EASA,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎損傷者(GFR值小於30毫升/每分鐘/1.73m2)禁用,仿單 20231128,202311281507,202311281507
EASA,成人,eGFR,0,90.00,mL/min/1.73m2,mL/min/1.73m2,不建議用於腎功能不全病人，血中肌酐或蛋白尿增加病人應小心使用。治療期間，腎功能不全之病人應注意因mesalazine引起之腎毒性。假如出現腎毒性症狀，應立即停止本品治療，並立即尋找醫師諮詢。,仿單 20231128,202311281503,202311281506
EBREZ,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,未曾進行過 BREZTRI AEROSPHERE 用於腎功能不全病人的正式藥物動力學研究。對於重度腎功能不全 (肌酸酐清除率 <=30 mL/min/1.73 m2) 或需要透析的末期腎病病人，僅限在預期效益超過可能的風險時，才可使用。,仿單 20241018,202410181129,202410181129
EBUT,成人,Clcr,0,60.00,mL/min,mL/min,1 mg， followed by 1 mg in 90-120 minutes if needed; repeat dosing sequence at intervals determined by patient response; usual interval is not less than 6 hours between dosing sequences.,Micromedex 20230612,202306121551,202306121551
ECOL2,成人,eGFR,29.99,0.01,mL/min/1.73m2,mL/min/1.73m2,Contraindicated.,仿單 20230404,202304041626,202304041626
ECOL4,成人,eGFR,29.99,0.01,mL/min/1.73m2,mL/min/1.73m2,Contraindicated.,仿單 20230404,202304041627,202304041627
EDDA,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,,201907241536,201804242350
EDUR1,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141207,202107141205
EDUR1,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141207,202107141205
EDUR2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Mild-to-moderate impairment: Initial: Reduce dose by 50%. Severe impairment: Use not recommended.,,201805281457,202303090942
EFEN,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141207,202107141205
EFEN,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141207,202107141205
EFEN1,成人,Clcr,0,9.99,mL/min,mL/min,Severe impairment: Avoid use.,Micromedex 20240813,202408131610,202408131610
EFEN1,成人,Clcr,10.00,50.00,mL/min,mL/min,Mild to moderate impairment: Initiate with 50% of the usual dosage.,Micromedex 20240813,202408131610,202408131610
EOPI,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141205,202107141205
EOPI,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141200,202107141205
ESIM,成人,Clcr,0,29.99,mL/min,mL/min,Use is contraindicated.,,201806251600,201806251604
ETRU,成人,Clcr,0.01,29.99,mL/min,mL/min,Use not recommended,仿單 20230306,202303061407,202303061407
EVORS,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091137,201912091137
IACE,成人,Clcr,59.99,0,mL/min,mL/min,Reduced Dose at Fixed-Time Intervals  An alternative rough guide for calculating a reduced dose at a fixed 12-hour interval in patients with known steady-state serum creatinine values is to divide the normally recommended dose by the patient's serum creatinine.,Micromedex 20210708,202107081134,202107081135
IACE,成人,Clcr,60.00,0,mL/min,mL/min,Reduced Dose at Fixed-Time Intervals  If serum concentrations are not available and the patient condition is stable， use the serum creatinine and creatinine clearance (CrCl) values to guide dose adjustment.   To calculate the dose for a fixed-time interval administered every 12 hours (after administration of normal loading dose of 7.5 mg/kg)， reduce the normal loading dose in proportion to the reduction in CrCl rate as follows:  maintenance dose every 12 hours = observed CrCl (mL/min)/normal CrCl (mL/min) x 7.5 mg/body weight (kg),Micromedex 20210708,202107081125,202107081135
IACET,成人,Clcr,0,10.00,mL/min,mL/min,兩次用藥至少間隔8小時,,201804142321,201804142321
IACL,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804111604,201804111604
IACTMV,成人,Clcr,0,60.00,mL/min,mL/min,不需為輕度或中度腎功能不全者調整劑量。目前尚未針對重度腎功能不全者使用Actemra之療效與安全性進行相關研究。,仿單 20240822,202106231359,202408221433
IACTMV10,成人,Clcr,0,60.00,mL/min,mL/min,不需為輕度或中度腎功能不全者調整劑量。目前尚未針對重度腎功能不全者使用Actemra之療效與安全性進行相關研究。,仿單 20240822,202408221501,202408221501
IAGG,成人,Clcr,0,30.00,mL/min,mL/min,劑量降低50%[仿單],,202312031616,201910251156
IAGG,成人,Clcr,0,59.90,mL/min,mL/min,CrCl <60 mL/minute: IV Loading dose: 25 mcg/kg administered over 5 minutes or less; Maintenance infusion: 0.075 mcg/kg/minute continued for up to 18 hours,,201804191220,201910251156
IALF,成人,Clcr,0,0,mL/min,mL/min,腎功能不全的病患應謹慎使用並考慮降低劑量,,201804141456,201804141456
IALI1,成人,Clcr,0,45.00,mL/min,mL/min,禁止使用,,201804301510,202303090942
IALI5,成人,Clcr,0,45.00,mL/min,mL/min,禁止使用,,201804301511,202303090943
IAMI2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804231747,202303090943
IAMP,成人,Clcr,0,9.99,mL/min,mL/min,change interval to every 12 to 16 hours,,,202303090939
IAMP,成人,Clcr,10.00,50.00,mL/min,mL/min,change interval to every 6 to 12 hours,,,202303090940
IAMPI,成人,Clcr,0,1.00,mL/min,mL/min,Intermittent hemodialysis: 1-2 g q12-24h， administer after dialysis on dialysis days for q24h dosing (assuming dialysis sessions are 3 times weekly); larger doses may be required with extended daily dialysis.,Micromedex 20240919,202409191216,202409191214
IAMPI,成人,Clcr,0,0.80,mL/min,mL/min,Continuous Renal Replacement Therapy: loading dose 2 g; maintenance dosage: (1) Continuous Venovenous Hemofiltration: 1-2 g q8-12h (2) Continuous Venovenous Hemodialysis: 1-2 g q8h (3) Continuous Venovenous Hemodialfiltration: 1-2 g q6-8h.,Micromedex 20240919,202409191220,202409191220
IAMPI,成人,Clcr,0,9.99,mL/min,mL/min,dose every 12 to 16 hours,Micromedex 20240919,202409191215,202409191214
IAMPI,成人,Clcr,0,0.90,mL/min,mL/min,Peritoneal Dialysis: 250 mg q12h,Micromedex 20240919,202409191217,202409191214
IAMPI,成人,Clcr,10.00,49.99,mL/min,mL/min,dose every 6 to 12 hours,Micromedex 20240919,202409191215,202409191214
IAMPI,成人,Clcr,50.00,999.00,mL/min,mL/min,dose every 6 hours,Micromedex 20240919,202409191214,202409191214
IAMPI5,成人,Clcr,0,1.00,mL/min,mL/min,Continuous hemofiltration: 250 mg to 2 g every 6 to 12 hours. Peritoneal dialysis: 250 mg every 12 hours. Hemodialysis: maintenance dose following hemodialysis.,Micromedex 20241110,202411101610,
IAMPI5,成人,Clcr,0.10,9.99,mL/min,mL/min,dose every 12 to 16 hours,Micromedex 20241110,202411101609,202411101610
IAMPI5,成人,Clcr,10.00,49.99,mL/min,mL/min,dose every 6 to 12 hours,Micromedex 20241110,202411101608,
IAMPI5,成人,Clcr,50.00,999.00,mL/min,mL/min,dose every 6 hours,Micromedex 20241110,202411101608,
IANO,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病或進行性腎損害或腎功能障礙之完全無尿病患不建議使用,,201907091128,201907100812
IARI,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201804191142,202303090944
IARI,成人,Clcr,30.00,50.00,mL/min,mL/min,Use caution; total clearance ~40% lower compared to patients with normal renal function. When used for thromboprophylaxis， the American College of Chest Physicians suggests a 50% reduction in dose or use of low-dose heparin instead of fondaparinux.,,201804191142,202303090944
IBENA,成人,Clcr,0,9.99,mL/min,mL/min,重度(GFR <10 mL/min)：間隔12-18小時給藥,仿單 20240813,202408131002,202408131003
IBENA,成人,Clcr,10.00,50.00,mL/min,mL/min,中度(GFR 10-50 mL/min)：間隔6-12小時給藥,仿單 20240813,202408131002,202408131003
IBENA,成人,Clcr,50.10,120.00,mL/min,mL/min,輕度(GFR>50mL/min)：間隔6小時給藥,仿單 20240813,202408130959,202408131003
IBFL,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎障礙的病患應謹慎使用,重症腎障礙或高氮血症患者不建議使用,201804261421,201804261421
IBIC,成人,eGFR,0,9.99,mL/min,mL/min,Administer 20% to 50% of the normal dose.,Micromedex Solutions. Accessed April 2， 2020.,201803281156,202004021546
IBIC,成人,eGFR,10.00,50.00,mL/min,mL/min,Administer 75% of the normal dose.,Micromedex Solutions. Accessed April 2， 2020.,201803281156,202004021546
IBLE1,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能不全者為禁忌,,201804301537,202303090944
IBOL,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804112354,202303090944
IBOL,成人,Clcr,30.00,39.00,mL/min,mL/min,調整成 3.0mg,,201804112354,202303090944
IBOL,成人,Clcr,40.00,49.00,mL/min,mL/min,調整成 3.3mg,,201804112354,202303090944
IBOL,成人,Clcr,50.00,60.00,mL/min,mL/min,調整成 3.5mg,,201804112353,202303090945
IBON,成人,Clcr,0,12.00,mL/min,mL/min,劑量減少50%,,201804112356,201804112356
IBON,成人,Clcr,12.00,50.00,mL/min,mL/min,劑量減少25%~50%,,201804112356,202303091002
IBON,成人,Clcr,50.00,80.00,mL/min,mL/min,劑量減少25%,,201804112356,202303091000
IBONV,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804112358,201804112358
IBRID,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804191446,201804191446
IBURO,成人,Clcr,0,999.00,mL/min,mL/min,No adjustment needed,[Micromedex],202412060957,202412060954
IBURO,成人,Clcr,0,15.00,mL/min,mL/min,1g/1g(每12小時500mg/500mg),[仿單],202412060954,202412060954
IBURO,成人,Clcr,16.00,30.00,mL/min,mL/min,2g/2g(每12小時1g/1g),[仿單],202412060955,202412060954
IBURO,成人,Clcr,31.00,999.00,mL/min,mL/min,4g/4g (每12小時2g/2g),[仿單],202412060956,202412060954
ICAG,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Initiate with the lower limit of the dosage range (accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations).,,201804231738,201804231738
ICAG1,成人,Clcr,0,999.00,mL/min,mL/min,Initiate at the lowest dose of the suggested dose ranges for all age groups and monitor serum calcium levels every 4 hours.,[Micromedex],202412101019,202412101019
ICAG1,成人,Clcr,1.00,999.00,mL/min,mL/min,Parenteral calcium should be administered only after careful assment of the indication and the calcum-phosphate balance should be monitored.,[仿單],202412101021,202412101023
ICAR2,成人,Clcr,16.00,40.00,mL/min,mL/min,第一天之建議劑量: 200mg/m2,仿單 20231204,202312041613,202312041613
ICAR2,成人,Clcr,41.00,59.00,mL/min,mL/min,第一天之建議劑量: 250mg/m2,仿單 20231204,202312041613,202312041613
ICEF1,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 1 -2 gm Q24-48H (+ extra 0.5-1 gm after dialysis),,,202303090959
ICEF1,成人,Clcr,0,10.00,mL/min,mL/min,1 -2 gm Q24-48H,,,202303090959
ICEF1,成人,Clcr,10.00,50.00,mL/min,mL/min,1 -2 gm Q12H,,,202303090959
ICEF1,成人,Clcr,50.00,90.00,mL/min,mL/min,1 -2 gm Q8H,,,202303090959
ICEF1,兒童,Clcr,5.00,20.00,mL/min,mL/min,10% of the normal daily dose given every 24 hr,,201803261632,201803261632
ICEF1,兒童,Clcr,20.00,40.00,mL/min,mL/min,25% of the normal dose divided every 12 hr,,201803261632,201803261632
ICEF1,兒童,Clcr,40.00,70.00,mL/min,mL/min,60% of the normal daily dose divided every 12 hr,,201803261632,202303090958
ICEFS,成人,Clcr,0,9.99,mL/min,mL/min,腎衰竭(Creatinine clearance < 10mL/min):不要超過2g/day。,仿單 20230809,202308091626,202308091626
ICEFT,成人,Clcr,0,5.00,mL/min,mL/min,0.5 g every 48 hours,,201803261635,202303090945
ICEFT,成人,Clcr,0,0,mL/min,mL/min,give initial 1 g loading dose followed by 1 g after each hemodialysis period,血液透析患者,201803261636,202303090945
ICEFT,成人,Clcr,6.00,15.00,mL/min,mL/min,0.5 g every 24 hours,,201803261635,202303090946
ICEFT,成人,Clcr,16.00,30.00,mL/min,mL/min,1 g every 24 hours,,201803261635,202303090946
ICEFT,成人,Clcr,31.00,50.00,mL/min,mL/min,1 g every 12 hours,,201803261634,202303090946
ICERE,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者不建議使用,,201804261423,201804261423
ICET,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 48 hours (after hemodialysis),Micromedex,201803261642,202011111046
ICET,成人,eGFR,10.00,29.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 24 hours,Micromedex,201803261640,202011111047
ICET,成人,eGFR,30.00,49.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 16 hours,Micromedex,201803261640,202011111047
ICET,成人,eGFR,50.00,90.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 12 hours,Micromedex,201803261640,202011111047
ICETR,成人,Clcr,0,10.00,mL/min,mL/min,重度腎功能不全者不建議使用,無相關研究應謹慎使用,201804231429,201810211205
ICIP2,成人,Clcr,0,4.00,mL/min,mL/min,依上述Clcr值調整，於透析完再給藥,,,202303090947
ICIP2,成人,Clcr,5.00,29.00,mL/min,mL/min,200 to 400 mg IV every 18 to 24 hours,400mg/day,,202303090947
ICIP2,成人,Clcr,30.00,120.00,mL/min,mL/min,無須調整劑量,800mg/day,,202303090947
ICIT3,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙者應謹慎使用,,201804191527,201804191527
ICLA1,成人,eGFR,0,20.00,mL/min/1.73m2,mL/min/1.73m2,Dose should be reduced by 50%,MICROMEDEX (2020-05-26),202005261654,202005261649
ICLA1,成人,Clcr,0,10.00,mL/min,mL/min,1 - 2gm q24h,Sanford Guide(Web) (2020-05-26),202005261658,202005261649
ICLA1,成人,Clcr,0,9.99,mL/min,mL/min,Loading dose: 1g; Maintenance dose: 50% of normal dose with same freqency,仿單,202005261644,202303090947
ICLA1,成人,Clcr,0,0,mL/min,mL/min,H/D: 1 ~ 2g q24h AD CAPD: 1 ~ 2g q24h,仿單,202005261647,202005261649
ICLA1,成人,Clcr,10.00,50.00,mL/min,mL/min,1 - 2gm q12-24h,Sanford Guide(Web) (2020-05-26),202005261657,202005261649
ICLAR2,成人,Clcr,0,30.00,mL/min,mL/min,[仿單]重度腎功能不全（GFR<30mL/min/1.73m2），應先謹慎評估，如果必須使用，每公斤體重的注射劑量不可超過 0.1 mmol/kg。每次掃描之注射不可超過一次。,,202001121050,202001121053
ICLEX,成人,Clcr,0,30.00,mL/min,mL/min,DVT prophylaxis in abdominal surgery， hip replacement， knee replacement， or in medical patients during acute illness: SubQ: 30 mg once daily.,,201804191144,202303090948
ICLI15,成人,Clcr,0,0,mL/min,mL/min,對於腎功能不全患者，應該謹慎注意,嚴重腎功能衰竭 嚴重腎功能衰竭患者最好使用特殊配方的氨基酸溶液,201804261519,201804261519
ICOL,成人,Scr,0.70,1.20,mg/dL,mg/dL,100-150mg Q6H-Q12H， approximate daily dose = 5mg/kg/day,300mg/day,,202303090948
ICOL,成人,Scr,1.30,1.50,mg/dL,mg/dL,75-115mg Q12H， approximate daily dose = 2.5-3.8mg/kg/day,150-230mg/day,,202303090948
ICOL,成人,Scr,1.60,2.50,mg/dL,mg/dL,66-150mg Q12H-Q24H， approximate daily dose = 2.5mg/kg/day,133-150mg/day,,202303090949
ICOL,成人,Scr,2.60,4.00,mg/dL,mg/dL,100-150mg Q36H， approximate daily dose = 1.5mg/kg/day,100mg/day,,202303090949
ICOL,成人,Clcr,10.00,29.99,mL/min,mL/min,1.5 mg/kg IM or IV every 36 hours,,,202303090949
ICOL,成人,Clcr,30.00,49.99,mL/min,mL/min,2.5 mg/kg IM or IV once daily or in 2 divided doses,,,202303090949
ICOL,成人,Clcr,50.00,79.00,mL/min,mL/min,2.5 to 3.8 mg/kg/day IM or IV in 2 divided doses,,,202303090949
ICOV,成人,Clcr,0,0,mL/min,mL/min,【腎功能損害的病患使用時】當methotrexate的排泄不足則會導致累積而增加methotrexate毒性的危險；即使少量methotrexate也可能導致嚴重的骨髓抑制和黏膜炎。因此必須增加folinate calcium劑量或延長治療的時間時，也須小心偵測methotrexate的濃度。,仿單 20240115,202401151530,202401151530
ICRA2,成人,Clcr,0,19.99,mL/min,mL/min,【熱病】: 750 mg once， then 500 mg q48h (Hemodialysis， CAPD， CRRT皆適用),,202112031347,202112031349
ICRA2,成人,Clcr,10.00,19.00,mL/min,mL/min,【250mg/day regimen】: 250mg q48h  【500mg/day regimen】: loading 500mg， then 250mg q48h 【750mg/day regimen】: loading 750mg， then 500mg q48h,,,201908291500
ICRA2,成人,Clcr,20.00,49.00,mL/min,mL/min,【250mg/day regimen】: no adjustment required  【500mg/day regimen】: loading 500mg， then 250mg q24h  【750mg/day regimen】: 750mg q48h 【熱病】: 750mg q48h,,,202112031348
ICRA2,成人,Clcr,50.00,120.00,mL/min,mL/min,無須調整劑量,,,202303090949
IDDA,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,資料來源:Micromedex,201907241538,201804242350
IDES,成人,Clcr,0,0,mL/min,mL/min,嚴重腎衰竭患者應小心使用，鐵和鋁的複合物之排除會因透析而增加，應考慮監測患者腎功能變化,,201804191458,201804191458
IDEXA,成人,Clcr,0,0,mL/min,mL/min,腎機能不全者不建議使用,,201804231401,201804231401
IDIF,成人,Clcr,10.00,20.99,mL/min,mL/min,正常劑量，給藥間隔為72小時，或正常每日劑量的三分之一，給藥間隔24小時,,,202303090949
IDIF,成人,Clcr,21.00,40.00,mL/min,mL/min,正常劑量，給藥間隔為48小時，或正常每日劑量的一半給藥間隔24小時,,,202303090949
IDIF,成人,Clcr,40.01,999.00,mL/min,mL/min,正常劑量，給藥間隔為24小時,,,202303090949
IDIG2,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120018,201804120018
IDIPE,成人,Clcr,0,25.00,mL/min,mL/min,嚴重腎功能不全者不建議使用,[仿單],201804261426,202312061943
IDIPH,成人,Clcr,0,10.00,mL/min,mL/min,給藥間隔 12-18 小時,,201804242359,201804242359
IDIPH,成人,Clcr,10.00,50.00,mL/min,mL/min,給藥間隔 6-12 小時,,201804242359,202303090950
IDIPH,成人,Clcr,50.00,0,mL/min,mL/min,給藥間隔 6 小時,,201804242358,202303090950
IDOR,成人,Clcr,0,10.00,mL/min,mL/min,Decrease dose by 50%,,201804191531,201804191531
IDOX,成人,Clcr,0,0.01,mL/min,mL/min,(Hemodialysis， ESRD) Give standard dosage after hemodialysis; may consider giving 75% of the original dose.,Micromedex 20231120,202311201130,202311201131
IDOX,成人,Clcr,0,0.03,mL/min,mL/min,(Hemodialysis， ESRD) Urothelial cancer receiving M-VAC: Methotrexate 15 mg/m2， Cisplatin 40 mg/m2， vinblastine 1.8 mg/m2， Doxorubicin 18 mg/m2 day 1; dialysis 1 hour after Cisplatin,Micromedex 20231120,202311201136,202311201138
IDOX,成人,Clcr,0,0.02,mL/min,mL/min,(Hemodialysis， ESRD) Urothelial cancer receiving VAC: Carboplatin 100 mg/m2， Vinblastine 3 mg/m2， Doxorubicin 22.5 mg/m2 on day 1; dialysis 24 hours after Carboplatin,Micromedex 20231120,202311201138,202311201138
IDYN,成人,Clcr,0,30.00,mL/min,mL/min,應從最低劑量開始使用，並密切監測病人腎功能,,201804141610,202303090951
IEND,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,降低50% 的劑量。,,201804301558,202303090951
IEND5,成人,Clcr,0,10.00,mL/min,mL/min,腎絲球過濾速率<10mL/min，降低 50% 的劑量。,20231012 仿單,202310121204,202310121205
IENH,成人,Clcr,0,29.99,mL/min,mL/min,No recommendation was established.,仿單 20230116,202301161546,202301161546
IEPH,成人,Clcr,0,0,mL/min,mL/min,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201804120027,201804120027
IESM,成人,Clcr,0,0,mL/min,mL/min,使用 0.6 mg.kg-1 之 rocuronium bromide為快速麻醉誘導之插管劑量時，這類病人之臨床作用時間預期可能會延長。無論使用何種麻醉技術，這類病人之推薦維持劑量為0.075-0.1 mg.kg-1之rocuronium bromide，而推薦輸注率為0.3~0.4 mg.kg-1.h-1,,201804160518,202303090951
IETP,成人,eGFR,29.99,0.01,mL/min/1.73m2,mL/min/1.73m2,500mg once daily,仿單 20230330,202303301109,
IETP,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis (HD): 0.5 gm q24h.  (If dosed within 6 hrs prior to HD， give 150 mg supplement after hemodialysis (AD). If dosed >6 hrs prior to HD， no AD supplement required).,Sanford Guide 20230330,202303301019,202303301103
IETP,成人,Clcr,29.99,0,mL/min,mL/min,0.5 gm q24h,Sanford Guide 20230330,202303301103,202303301103
IFADI,成人,Clcr,49.00,0,mL/min,mL/min,Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.,uptodate 20200803,202003121413,202008031022
IFAM,成人,Clcr,0,49.99,mL/min,mL/min,Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.,,201804131612,201910141634
IFAS,成人,Clcr,0,30.00,mL/min,mL/min,須謹慎使用,,201805021609,202303090952
IFAS0,成人,Clcr,0,30.00,mL/min,mL/min,須謹慎使用,,201805021609,202303090952
IFIR,成人,eGFR,0,49.99,mL/min/1.73m2,mL/min/1.73m2,use with caution.,,201902271525,202303090952
IFIR8,成人,eGFR,0,49.99,mL/min/1.73m2,mL/min/1.73m2,use with caution.,,201812191213,202303090953
IFLUC,成人,Clcr,0,1.00,mL/min,mL/min,規則接受血液透析病人: 每次血液透析後給藥。,仿單 20240104,202401042127,202401042125
IFLUC,成人,Clcr,10.00,20.00,mL/min,mL/min,單劑量治療時不須調整劑量，但對腎功能不全者多次給藥時，在第一、二天，可給予正常的劑量，之後改為給藥間隔72小時，或每日給予正常每日劑量的三分之一。,仿單 20240104,202401042125,202401042125
IFLUC,成人,Clcr,21.00,40.00,mL/min,mL/min,單劑量治療時不須調整劑量，但對腎功能不全者多次給藥時，在第一、二天，可給予正常的劑量，之後改為給藥間隔48小時，或每日給予正常每日劑量的一半。,仿單 20240104,202401042125,202401042125
IFMR,成人,Clcr,5.00,0,mL/min,mL/min,0.5g/day,2021/01/28廠商提供資訊,202101281551,202101281542
IFMR,成人,Clcr,25.00,5.00,mL/min,mL/min,1g/day,2021/01/28廠商提供資訊,202101281542,202101281542
IFMR,成人,Clcr,50.00,25.00,mL/min,mL/min,2g/day,2021/01/28廠商提供資訊,202101281541,202101281542
IFMR,成人,Clcr,60.00,0,mL/min,mL/min,無相關紀載,仿單,202101251230,202303090953
IFOLI,成人,Clcr,0,0,mL/min,mL/min,病人若有腹水，胸膜滲透液，腎功能障礙或Hydration不夠時會延遲methotrexate排出，應考慮增加Folina劑量或延長治療時間,,201804191521,201804191521
IFRA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in severe renal impairment; accumulation may occur with repeated dosing， increasing the risk for bleeding.,,201804191146,202303090953
IFRA5,成人,Clcr,30.00,0,mL/min,mL/min,對於顯著腎衰竭之病人(其定義為肌酸酐>3倍ULN)，應調整dalteparin的劑量， 使抗Xa因子濃度在注射dalteparin後4~6小時維持在1 IU/mL (範圍：0.5-1.5 IU/mL)的治療 濃度。如果抗Xa因子濃度低於或高於治療範圍，應分別用注射針筒製劑增加或降低劑量， 並於投予3-4個新劑量之後重新檢測抗Xa因子濃度。重複進行此種劑量調整，直至達到 抗Xa因子治療濃度為止。,仿單,202110061300,202110061301
IFUR1,成人,Clcr,0,9.99,mL/min,mL/min,750 mg every 24 hr,,201803261645,202303090953
IFUR1,成人,Clcr,0,0,mL/min,mL/min,a supplemental dose should be given after hemodialysis,血液透析患者,201803261645,202303090953
IFUR1,成人,Clcr,10.00,20.00,mL/min,mL/min,750 mg every 12 hr,,201803261644,202303090953
IFYT,成人,Clcr,15.00,50.00,mL/min,mL/min,75%劑量,,201805021612,201805021612
IFYT,成人,Clcr,50.00,120.00,mL/min,mL/min,100%劑量,,201805021612,201805021612
IGEN8,成人,Scr,1.40,99.00,mg/dL,mg/dL,(if to increase dosing interval)Multiply the SCr by a factor of 8 to get dosing interval in hours.(eg， a 60 kg patient with SCr of 2 mg/dL at a dose of 1 mg/kg would receive 60 mg every 16 hours (SCr x 8)) (if to decrease dose)Administer usual initial dose， then reduce dose by dividing initial dose by SCr and administer every 8 hours (eg， a 60 kg patient with SCr of 2 mg/dL at a dose of 1 mg/kg would receive 60 mg initially， then 30 mg every 8 hours (initial dose divided by SCr)),[Micromedex],202412251128,202412251209
IGEN8,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis， intermittent (thrice weekly): Urinary tract infection: IM， IV: 1 to 1.5 mg/kg/dose 3 times weekly after dialysis on dialysis days. Systemic gram-negative infection: IM， IV: 2 to 3 mg/kg/dose 3 times weekly after dialysis on dialysis days.,[UpToDate],202412251214,202412251216
IGEN8,成人,Clcr,1.00,19.00,mL/min,mL/min,(High-dose， extended-interval dosing) IV: Administer usual dose once， then determine subsequent dose and interval based on serum concentration monitoring. Some published protocols would recommend conventional/traditional dosing in these patients. (Conventional/traditional dosing)IM， IV: Administer usual dose every 36 to 48 hours; adjust dose and/or interval based on gentamicin serum concentrations.,[UpToDate],202412251212,202412251214
IGEN8,成人,Clcr,20.00,39.00,mL/min,mL/min,(High-dose， extended-interval dosing)IV: Administer every 48 hours; adjust dose and/or interval based on gentamicin serum concentrations. (Conventional/traditional dosing)IM， IV: Administer usual dose every 24 hours; adjust dose and/or interval based on gentamicin serum concentrations.,[UpToDate],202003150919,202412251209
IGEN8,成人,Clcr,40.00,59.00,mL/min,mL/min,(High-dose， extended-interval dosing)IV: Administer every 36 hours; adjust dose and/or interval based on gentamicin serum concentrations. (Conventional/traditional dosing)IM， IV: Administer usual dose every 12 hours; adjust dose and/or interval based on gentamicin serum concentrations.,[UpToDate],202003150919,202412251210
IGEN8,成人,Clcr,60.00,120.00,mL/min,mL/min,(High-dose， extended-interval dosing)IV: Administer every 24 hours; adjust dose and/or interval based on gentamicin serum concentrations. (Conventional/traditional dosing)IM， IV: No dosage adjustment necessary.,[UpToDate],202003150919,202412251210
IGENT,成人,Clcr,20.00,39.00,mL/min,mL/min,usual mg/kg dose every 48 hours (once-daily dosing),,,202303090954
IGENT,成人,Clcr,40.00,59.00,mL/min,mL/min,usual mg/kg dose every 36 hours (once-daily dosing),,,202303090954
IGENT,成人,Clcr,60.00,120.00,mL/min,mL/min,usual mg/kg dose every 24 hours (once-daily dosing),,,202303090954
IGLY1,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之病患應謹慎使用,仿單,201804121422,202201120909
IGLY3,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之病患應謹慎使用,仿單,202201120909,202201120909
IHALA,成人,Clcr,15.00,49.00,mL/min,mL/min,Reduce initial dose to 1.1 mg/m2,202106仿單,202106171505,202106171519
IHYC,成人,Clcr,20.00,39.00,mL/min,mL/min,0.75mg/m2,,201805021619,202303090955
IHYC,成人,Clcr,40.00,60.00,mL/min,mL/min,不需調整,,201805021619,202303090955
IIG3,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.,,201804231623,202303090955
IINV,成人,Clcr,0,50.00,mL/min,mL/min,不建議使用,,202312031017,
IINV,成人,Clcr,50.00,80.00,mL/min,mL/min,156 mg IM on day 1 and 117 mg IM 1 week later,maintenance， 78 mg IM monthly,202312031017,
IINV2,成人,Clcr,0,50.00,mL/min,mL/min,不建議使用,,201804142336,201804142336
IINV2,成人,Clcr,50.00,80.00,mL/min,mL/min,156 mg IM on day 1 and 117 mg IM 1 week later,maintenance， 78 mg IM monthly,201804142336,202303090959
IINVZ,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 500 mg IV every 24 hours; supplemental dose of 150 mg after hemodialysis if last dose administered within 6 hours prior to hemodialysis,Micromedex 20211005,202110051935,202110051934
IINVZ,成人,Clcr,30.00,0,mL/min,mL/min,CrCl 30 mL/min or less， 500 mg IV every 24 hours,Micromedex 20211005,202110051934,202110051934
IKCL,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261451,202303090955
IKCL2,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261452,201804261452
IKCL5S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261453,201804261453
IKCL6,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261455,201804261455
IKCL7S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261456,201804261456
IKCL8S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261456,201804261456
IKEP,成人,Clcr,0,0,mL/min,mL/min,洗腎患者500 to 1000 mg IV every 24 hours，洗腎後再補充250-500mg。,,202312031022,201804160416
IKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IV every 12 hours,,201804160412,201804160416
IKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IV every 12 hours,,201804160412,202303090956
IKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IV every 12 hours,,201804160411,202303090956
IKETO,成人,Clcr,0,30.00,mL/min,mL/min,腎功能不全者，建議給藥間隔為 每6小時 每次15mg,最高每日劑量為60 mg/day,201804141541,201912091116
ILATO,成人,Clcr,0,60.00,mL/min,mL/min,30mg IM stat for 1 dose OR 15mg IM q6h， MAX 60mg/day;  15mg IV stat for 1 dose OR 15mg IV q6h， MAX 60mg/day.,仿單 20231003,202310031403,202310031404
ILEV,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201808231126,202303090956
ILEV2,成人,Clcr,0,0,mL/min,mL/min,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201804120029,201804120029
ILEVET,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IVD every 12 hours,,201903240936,201903241015
ILEVET,成人,Clcr,0,0,mL/min,mL/min,End-stage renal disease (ESRD) requiring hemodialysis: 500 to 1000 mg IVD QD (治療首日建議劑量為750 mg，洗腎後建議補充劑量為250至500 mg),,201903241015,201903241022
ILEVET,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IVD every 12 hours,,201903240936,201903241015
ILEVET,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IVD every 12 hours,,201903240936,201903241015
ILFT,成人,Clcr,0,4.99,mL/min,mL/min,Loading dose 1-2g， followed by 0.5-1g Q24-48H,UpToDate 2023-01-12,202301121140,202301121139
ILFT,成人,Clcr,0,0,mL/min,mL/min,Loading dose 1-2 g after each hemodialysis; maintenance dose as noted above based on ClCr,Hemodialysis. UpToDate 2023-01-12,202301121148,202301121148
ILFT,成人,Clcr,0,9.99,mL/min,mL/min,2 gm q24-48h,Sanford Guide 2023-01-15,202301150907,202301121148
ILFT,成人,Clcr,0,0.01,mL/min,mL/min,2 gm q24h-48h; extra 1 gm after hemodialysis,Hemodialysis. Sanford Guide 2023-01-15,202301150911,202301121148
ILFT,成人,Clcr,5.00,9.00,mL/min,mL/min,Loading dose 1-2g， followed by 0.5-1g Q12-24H,UpToDate 2023-01-12,202301121140,202301121139
ILFT,成人,Clcr,10.00,29.00,mL/min,mL/min,Loading dose 1-2g， followed by 1-2g Q12-24H,UpToDate 2023-01-12,202301121139,202301121139
ILFT,成人,Clcr,10.00,50.00,mL/min,mL/min,2 gm q8-12h,Sanford Guide 2023-01-15,202301150907,202301150909
ILFT,成人,Clcr,30.00,50.00,mL/min,mL/min,Loading dose 1-2g， followed by 1-2g Q8-12H,UpToDate 2023-01-12,202301121138,202301121138
ILIG2,成人,Clcr,0,30.00,mL/min,mL/min,Administer maintenance infusion at lower rate with close monitoring,Micromedex 20210217,202102171142,202102171143
ILIP20,成人,Clcr,0,0,mL/min,mL/min,未接受透析治療之嚴重腎功能不全者不建議使用,,201804261436,201804261436
IMAG2,成人,Clcr,0,0,mL/min,mL/min,有腎功能障礙之患者，高鎂血症患者必須審慎投與,,201804261459,201804261459
IMAN1,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病或進行性腎損害或腎功能障礙之完全無尿病患不建議使用,,201804121420,202303090956
IMAR4,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全病患應小心使用，以減低發生危險副作用的風險,,201804191601,201804191601
IMARS,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者應小心使用，以減低發生危險副作用的風險,,201804191602,201804191602
IMAXI,成人,Clcr,0,10.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.25g Q24h;輕至中度非泌尿道感染:0.25g Q24h;嚴重感染:0.5g Q24h;非常嚴重或有生命威脅之感染:1g Q24h,,201803261647,202303090956
IMAXI,成人,Clcr,0,0,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:0.5g Q24h;嚴重感染:0.5g Q24h;非常嚴重或有生命威脅之感染:0.5g Q24h,血液透析患者,201803261647,202303090956
IMAXI,成人,Clcr,11.00,29.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:0.5g Q24h;嚴重感染:1g Q24h;非常嚴重或有生命威脅之感染:2g Q24h,,201803261647,202303090956
IMAXI,成人,Clcr,30.00,50.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:1g Q24h;嚴重感染:2g Q24h;非常嚴重或有生命威脅之感染:2g Q12h,,201803261646,202303090956
IMAXI,成人,Clcr,50.00,199.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q12h;輕至中度非泌尿道感染:1g Q12h;嚴重感染:2g Q12h;非常嚴重或有生命威脅之感染:2g Q8h,,201803261646,202303090956
IMENO,成人,Clcr,0,59.99,mL/min,mL/min,對於腎機能障礙，妊娠患者若靜脈注射四環素治療，每日劑量超過2公克將致肝機能衰竭。對於治療高危險群病人(妊娠或已知腎功能或肝功能不全)在治療前和治療期間均需作肝功能和腎功能檢查。,仿單 20240521,202405211545,202405211542
IMENO,成人,Clcr,0,5.00,mL/min,mL/min,Hemodialysis， Prolonged intermittent renal replacement therapy (PIRRT)， Continuous renal replacement therapy: No adjustment necessary.,Micromedex 20240521,202405211541,202405211541
IMENO,成人,Clcr,0,60.00,mL/min,mL/min,Reduce total dose or extend dosing interval. Do not exceed 200 mg in 24 hours.,Micromedex 20240521,202405211542,202405211542
IMEP2,成人,Clcr,0,10.00,mL/min,mL/min,劑量減半，每24小時投予一次,1gm/day,,202303090956
IMEP2,成人,Clcr,10.00,25.00,mL/min,mL/min,劑量減半，每12小時投予一次,1gm/day,,202303090956
IMEP2,成人,Clcr,26.00,50.00,mL/min,mL/min,一般劑量，每12小時投予一次,2gm/day,,202303090956
IMETE2,成人,Clcr,60.00,0,mL/min,mL/min,Use caution in patients with renal impairment.,仿單 20230317,202303171947,202303171947
IMID5,成人,Clcr,0.10,0,mL/min,mL/min,腎功能受損的患者，藥物動力學和健康志願者大致相同。不過，在慢性腎病患者中，目前已證實會出現α-hydroxymidazolam蓄積現象，這可能會促進midazolam的臨床作用，繼而導致鎮靜作用的持續時間延長。,仿單 20240130,202401301712,202401301712
IMORP,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50% or consider alternative opioid analgesics,,201804141507,201804141508
IMORP,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 25%,,201804141507,202303091001
IMTX2,成人,Clcr,0,15.00,mL/min,mL/min,嚴重腎功能不全禁用,,201804301634,202303090956
IMUT,成人,Clcr,0,50.00,mL/min,mL/min,本藥經由腎臟排泄，腎功能障礙患者請小心並減量使用,仿單,202104061013,202312031057
IMV13,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,腎功能障礙者謹慎使用。,,201804231722,202303090957
INEP,成人,Clcr,0,0,mL/min,mL/min,若引起腎功能低下，則須先補充足量水分及電解質,,201804261430,202303090957
INOB,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IV every 12 hours,,201804141516,201804141516
INOB,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IV every 12 hours,,201804141514,201804141515
INOB,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IV every 12 hours,,201804141514,202303091002
IOLA5,成人,Clcr,0,30.00,mL/min,mL/min,禁忌,,201804301602,202303090957
IOLI3,成人,Clcr,0,0,mL/min,mL/min,腎功能不全的患者應謹慎使用,,201804261523,201804261523
IOPT,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling. Use caution in severe impairment， anuria， and in setting of combined renal and hepatic disease.,,201804181143,202303090957
IORE,成人,Clcr,0,29.90,mL/min,mL/min,藥品仿單：禁忌使用在ClCr<30 mL/min的患者。 UPTODATE：Reduce dose from 85 mg/m2 to 65 mg/m2.,,201803221503,201811081514
IOXA,成人,Clcr,0,30.00,mL/min,mL/min,Reduce dose to 65 mg/m(2),仿單 20240103,202401031509,202401031511
IOXA1,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Consider giving 50% of the original dose.,[Micromedex]20241205,202412051621,202412051621
IOXA1,成人,Clcr,0,30.00,mL/min,mL/min,Reduce the oxaliplatin dose to 65 mg/m(2),[Micromedex]20241205,202412051620,202412051621
IOZE4,成人,Clcr,0,60.00,mL/min,mL/min,腎功能不全的病人不需調整劑量，在包含末期腎病(ESRD)的腎功能不全受試者中，未觀察到semaglutide 藥物動力學 (PK)有臨床相關性的改變,仿單 20240528,202405281404,202405281404
IPAM2,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者劑量應該減低,,201804191507,201804191507
IPAR,成人,Clcr,15.00,150.00,mL/min,mL/min,總劑量(mg) = ( 目標AUC) x (GFR+25),,201804301604,202303090957
IPAR,成人,Clcr,16.00,40.00,mL/min,mL/min,200 mg/m2,202106仿單,202106171700,202303090957
IPAR,成人,Clcr,41.00,59.00,mL/min,mL/min,250 mg/m2,202106仿單,202106171701,202303090957
IPCN3,成人,eGFR,0.01,9.99,mL/min,mL/min,Administer 20% to 50% of the normal dose,(Aronoff 2007),202004021527,202004021523
IPCN3,成人,eGFR,10.00,50.00,mL/min,mL/min,Administer 75% of the normal dose,(Aronoff 2007),202004021528,202004021523
IPCN3,成人,Clcr,0.01,9.99,mL/min/1.73 m^2,mL/min/1.73 m^2,administer full loading dose， followed by 50% loading dose every 8 to 10 hours,Manufacturer's labeling,201803051606,202004021523
IPCN3,成人,Clcr,10.00,130.00,mL/min/1.73 m^2,mL/min/1.73 m^2,administer a full loading dose， followed by 50% loading dose every 4 to 5 hours,Manufacturer's labeling,201803051608,202004021523
IPEGA,成人,Clcr,0,29.99,mL/min,mL/min,Reduce to 135 mcg/wk; if severe adverse reactions develop， reduce to 90 mcg/wk; if intolerance persists， discontinue therapy.,血液透析病人:Reduce to 135 mcg/wk; if severe adverse reactions develop， reduce to 90 mcg/wk; if intolerance persists， discontinue therapy.,,202303090957
IPERD,成人,Clcr,0,0,mL/min,mL/min,Titrate infusion gradually,,201804121507,201804121507
IPET,成人,Clcr,0,10.00,mL/min,mL/min,Reduce initial dose ，give 50% of the normal dose at the usual intervals,,201804141520,202303090959
IPET,成人,Clcr,10.00,50.00,mL/min,mL/min,Give 75% of the normal dose at the usual intervals,,201804141519,202303091001
IPEY,兒童,eGFR,0,999.99,mL/min/1.73m2,mL/min/1.73m2,use with caution. (has not been studied) 應根據Caffeine血中濃度來調整。,,201812091137,202312031537
IPHE,成人,Clcr,0,30.00,mL/min,mL/min,Reduce dose. Severe: Contraindicated.,,201809041537,202303091001
IPRI,成人,Clcr,0,40.00,mL/min,mL/min,Initiate at 50% of usual dosage  最大劑量為單一劑量每公斤體重0.2毫克(0.2mg/kg/dose)。,每日總劑量不可超過每公斤體重0.5毫克。,201804141427,201804141427
IPRIM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能受損的病患，因顯影劑的排除較慢，應權衡利弊得失後再使用本品,當再次使用於腎功能受損病患前需確認有足夠的時間排除體內的顯影劑,201804212357,201804212359
IPRO6,成人,Clcr,0,29.99,mL/min,mL/min,嚴重腎功能不全 (CrCl < 30mL/min) 或正在接受透析治療的病人發生低血鈣症的風險較高。對嚴重腎功能不全或正在接受透析治療的病人投予時，應權衡其效益風險概況。強烈建議針對血鈣與礦物質濃度 (磷和鎂) 進行臨床監視。對嚴重腎功能不全或正在接受透析治療的病人，適量補充鈣質與維生素 D 是極為重要的一環。,仿單 20240508,202405081503,202405081504
IPUL,成人,Clcr,0,10.00,mL/min,mL/min,CrCl < or =10 mL/minute and Hemodialysis， intermittent (thrice weekly):33% (or less) of usual total daily dose.,UpToDate 20221219,202212191609,202212200902
IPUL,成人,Clcr,10.00,60.00,mL/min,mL/min,50% of usual total daily dose.,UpToDate 20221219,202212191608,202212191609
IRAPI,成人,Clcr,0,9.99,mL/min,mL/min,ESRD requiring intermittent hemodialysis (IHD): 50 mg as a single dose， administered after dialysis,,201812110943,201812110946
IRAPI,成人,Clcr,10.00,29.99,mL/min,mL/min,50 mg as a single dose,,201812110943,201812110945
IRAPI,成人,Clcr,30.00,49.99,mL/min,mL/min,100 mg as a single dose,,201812110942,201812110945
IRHO1,成人,Clcr,0,120.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer's labeling; use with caution.,Lexidrug 20240414,202404141011,202404141011
IRIN4,成人,Clcr,0,0,mL/min,mL/min,腎機能不全者應謹慎投與,,201804231404,201804231404
IRIS,成人,Clcr,0,0,mL/min,mL/min,建議起始劑量是第一週每日服用risperidone 0.5 mg 兩次，第二週則增加為每日口服1 mg 兩次或每日服用2 mg 一次。若病人對每日服用至少2 mg 的耐受度佳，即可每兩週注射RISPERDAL CONSTAR 25 mg,,201804142343,202303091000
IROP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者通常不需要調整劑量,但慢性腎衰竭病人常伴有酸中毒或血漿蛋白減少，其發生全身性毒性作用之危險性較高,201804191557,201804191557
ISAB,成人,Clcr,0,9.99,mL/min,mL/min,No dosage adjustment necessary. Monitor closely for adverse effects due to accumulation of metabolites， particularly with prolonged courses of therapy. A dose of 500 mg every 12 hours may be adequate to achieve therapeutic plasma levels for nonsevere non-Clostridioides difficile infections.,Lexidrug 20240419,202404191019,202404191019
ISAX,成人,Clcr,30.00,0.01,mL/min,mL/min,Not recommended.,仿單 20230321,202303211634,202303211634
ISEF,成人,Clcr,0,30.00,mL/min,mL/min,靜脈注射每日最大劑量為一天400毫克,仿單,202201061542,202303091001
ISEF,成人,Clcr,5.00,29.00,mL/min,mL/min,200 to 400 mg IV every 18 to 24 hours; alternatively， may give 400 mg every 24 hours for CrCl less than 30 mL/min/1.73 m(2).,Micromedexs 20220106,202201061554,202201061556
ISEF,成人,Clcr,31.00,60.00,mL/min,mL/min,靜脈注射每日最大劑量為一天800毫克,仿單,202201061542,202303091000
ISEV,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,202303090959
ISEV,成人,Clcr,15.00,25.00,mL/min,mL/min,以標準劑量為最大劑量，給藥三天後劑量減半,,,202303090959
ISIMD,成人,Clcr,0,30.00,mL/min,mL/min,Contraindication. Avoid use.,,201809101151,202303090959
ISIMD,成人,Clcr,30.10,50.00,mL/min,mL/min,Simdax must be used with caution in patients with mild to moderate renal impairment.,,201809101152,201809101152
ISLQ,成人,Clcr,10.00,0,mL/min,mL/min,嚴重腎功能不全、末期腎病病人：不建議使用，因為lixisenatide在這些病人身上的治療經驗不足。,仿單 20230529,202305290840,202305290843
ISLQ,成人,Clcr,59.00,10.00,mL/min,mL/min,輕、中度腎功能不全：使用時可能需頻繁監測血糖並調整劑量。,仿單 20230529,202305290842,202305290843
ISOBI,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙的患者應謹慎投與,,201804261507,201804261507
ISOLM,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231408,201804231408
ISOO,成人,Clcr,0,0.01,mL/min,mL/min,Patients on hemodialysis should receive a maintenance dose of 250 or 500 mg amoxicillin/125 mg clavulanic acid every 24 hours， with a supplemental dose given both during and at the end of dialysis,Micromedex 20210318,202103181208,202103181206
ISOO,成人,Clcr,0.10,10.00,mL/min,mL/min,The suggested dose is 250 or 500 mg amoxicillin/125 mg clavulanic acid every 24 hours.,Micromedex 20210318,201803051616,202103181210
ISOO,成人,Clcr,0.10,9.99,mL/min,mL/min,先靜脈注射1劑1.2gm，然後再每24小時0.6gm. 洗腎後可能必須額外增加1劑0.6gm.,仿單,202103181144,202103181210
ISOO,成人,Clcr,10.00,29.99,mL/min,mL/min,先靜脈注射1劑1.2gm，然後再每12小時0.6gm.,仿單,202103181142,202103181146
ISOO,成人,Clcr,10.00,30.00,mL/min,mL/min,The suggested dose is 250 mg to 500 mg amoxicillin/125 mg clavulanic acid every 12 hours.,Micromedex 20210318,201803051616,202103181205
ISOO,成人,Clcr,30.00,60.00,mL/min,mL/min,無須改變劑量,仿單,202103181140,202303091000
ISTO,成人,Clcr,0,15.00,mL/min,mL/min,每日二次，每次投與 200 毫克,仿單,202012031653,202303091000
ISTO,成人,Clcr,0,0.01,mL/min,mL/min,循環中Cimetidine濃度會因血液透析而降低，因此本品須於透析最後階段給藥。,仿單,202012031652,202012031655
ISTO,成人,Clcr,15.00,30.00,mL/min,mL/min,每日三次，每次 200 毫克,仿單,202012031654,202303090959
ISTO,成人,Clcr,30.00,50.00,mL/min,mL/min,每日四次，每次 200 毫克,仿單,202012031655,202303091000
ISUB,成人,Clcr,5.00,14.00,mL/min,mL/min,1.5-3g every 24 hours,,201803261539,202303090959
ISUB,成人,Clcr,15.00,29.00,mL/min,mL/min,1.5-3g every 12 hours,,201803261538,202303091001
ISUB,成人,Clcr,30.00,199.00,mL/min,mL/min,1.5-3g every 6 to 8 hours,,201803261538,201803261603
ITAP,成人,Clcr,0,20.00,mL/min,mL/min,2.25g every 8 hours;院內感染性肺炎2.25g every 6 hours,,201803261549,202303090957
ITAP,成人,Clcr,0,0,mL/min,mL/min,2.25g every 12 hours plus 0.75 g after each dialysis session ;院內感染性肺炎2.25g every 8 hours plus 0.75 g after each dialysis session,血液透析患者,201803261550,202303090957
ITAP,成人,Clcr,20.00,40.00,mL/min,mL/min,2.25g every 6 hours; 院內感染性肺炎3.375g every 6 hours,,201803261544,202303091001
ITAR,成人,Clcr,0,40.00,mL/min,mL/min,(含血液透析病人)治療第四天起每日給予三分之一的維持劑量，或以起始劑量每三日給藥。 Maintenance dose: 2mg/kg or 4mg/kg Q24H; 6mg/kg or 12mg/kg Q72H,仿單 20230317,,202411061519
ITAR,成人,Clcr,29.99,0,mL/min,mL/min,(Hemodialysis) Load as usual， then: Complicated skin/soft tissue， pneumonia， complicated UTI: 6 mg/kg q72h; Bone & joint infection， endocarditis: 12 mg/kg q72h.,Sanfrod Guide 20230317,202303171636,202411061519
ITAR,成人,Clcr,40.00,60.00,mL/min,mL/min,治療第四天起改為每日給予減半的維持劑量，或以起始劑量隔日給藥。 Maintenance dose: 3mg/kg or 6mg/kg Q24H; 6mg/kg or 12mg/kg Q48H,仿單 20230317,,202411061519
ITAR,成人,Clcr,80.00,30.00,mL/min,mL/min,Load as usual， then: Complicated skin/soft tissue， pneumonia， complicated UTI: 6 mg/kg q48h; Bone & joint infection， endocarditis: 12 mg/kg q48h.,Sanford Guide 20230317,202303171634,202411061519
ITHIO,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,75% of usual dose at normal dosage interval,Micromedex 20241121,202411211601,202411211602
ITHYR,成人,Clcr,0,0,mL/min,mL/min,倚賴透析的末期腎臟病病人排泄 Thyrogen的速度非常慢，因此會延長提高 TSH 濃度的作用，須謹慎觀察。,,201804112350,201804112350
ITIE5,成人,Clcr,0,5.00,mL/min,mL/min,若同時接受血液透析者，可用ClCr=6~20min/mL的建議劑量，給藥時間分別為透析後與12小時後,500mg Q12H,,202303091002
ITIE5,成人,Clcr,6.00,20.00,mL/min,mL/min,250mg Q12H(原1gm/day， 1.5gm/day， 2gm/day)， 500mg Q12H(原3gm/day， 4gm/day),500mg Q12H,,202303091000
ITIE5,成人,Clcr,21.00,40.00,mL/min,mL/min,250mg Q12H(原1gm/day)， 250mg Q8H(原1.5gm/day)， 250mg Q6H(原2gm/day)， 500mg Q8H(原3gm/day)， 500mg Q6H(原4gm/day),500mg Q6H,,202303091000
ITIE5,成人,Clcr,41.00,70.00,mL/min,mL/min,250mg Q8H(原1gm/day)， 250mg Q6H(原1.5gm/day)， 500mg Q8H(原2gm/day)， 500mg Q6H(原3gm/day)， 750mg Q8H(原4gm/day),750mg Q8H,,202303091000
ITIEN,成人,Clcr,0,5.00,mL/min,mL/min,若同時接受血液透析者，可用ClCr=6~20min/mL的建議劑量，給藥時間分別為透析後與12小時後,500mg Q12H,201907111034,202303091000
ITIEN,成人,Clcr,6.00,20.00,mL/min,mL/min,250mg Q12H(原1gm/day， 1.5gm/day， 2gm/day)， 500mg Q12H(原3gm/day， 4gm/day),500mg Q12H,201907111034,202303091002
ITIEN,成人,Clcr,21.00,40.00,mL/min,mL/min,250mg Q12H(原1gm/day)， 250mg Q8H(原1.5gm/day)， 250mg Q6H(原2gm/day)， 500mg Q8H(原3gm/day)， 500mg Q6H(原4gm/day),500mg Q6H,201907111034,202303091000
ITIEN,成人,Clcr,41.00,70.00,mL/min,mL/min,250mg Q8H(原1gm/day)， 250mg Q6H(原1.5gm/day)， 500mg Q8H(原2gm/day)， 500mg Q6H(原3gm/day)， 750mg Q8H(原4gm/day),750mg Q8H,201907111034,202303090959
ITPN1,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261532,201804261532
ITPN1A,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261527,201804261528
ITPN2,成人,eGFR,0,59.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261528,201804261528
ITPN2A,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261529,201804261529
ITPN3,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261529,201804261529
ITPNP1,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261531,201804261531
ITPNP2,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261531,201804261531
ITPNP3,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261532,201804261532
ITRAM,成人,Clcr,0,30.00,mL/min,mL/min,increase dosing interval to 12 hours,MAX 200 mg/day,201804141523,201804141523
ITRAN,成人,Scr,1.36,2.83,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose twice daily,,201804231437,202303090959
ITRAN,成人,Scr,2.83,5.66,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose once daily,,201804231438,202303091001
ITRAN,成人,Scr,5.66,99.00,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose every 48 hours or 5 mg/kg/dose once daily,,201804231438,201804231439
IVAN1,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: Less than 70 kg， 1000-mg loading dose and then 500-mg maintenance dose infused over last 30 minutes of dialysis; 70 to 100 kg， 1250-mg loading dose and then 750-mg maintenance dose infused over last 60 minutes of dialysis; greater than 100 kg， 1500-mg loading dose and then 1000-mg maintenance dose infused over last 90 minutes of dialysis,Micromedex 20201123,202011231000,202011231001
IVAN1,成人,Clcr,60.00,0,mL/min,mL/min,Renal impairment (adult and pediatric): 15 mg/kg initially and then optimize dose and interval based on serum drug concentrations,Micromedex 20201123,202011230958,202011231001
IVAN1,成人,Clcr,100.00,0,mL/min,mL/min,劑量是每天mg之腎絲球過濾速率ml/min 的15倍，請依此參照100mL/min:1545mg/24hr; 90mL/min:1390mg/24hr; 80mL/min:1235mg/24hr; 70mL/min:1080mg/24hr; 60mL/min:925mg/24hr; 50mL/min:770mg/24hr; 40mL/min:620mg/24hr; 30mL/min:465mg/24hr; 20mL/min:310mg/24hr; 10mL/min:155mg/24hr;最初劑量不可少於15mg/kg，對中度至重度腎不全患者亦同。,仿單,202011230948,202011231001
IVANC,成人,Clcr,0.01,20.00,mL/min,mL/min,15-20 mg/kg q48h,Sanford Guide 20230414,202304141415,202304141415
IVANC,成人,Clcr,20.00,49.00,mL/min,mL/min,15-20 mg/kg q24h,Sanford Guide 20230414,202304141415,202304141414
IVANC,成人,Clcr,50.00,100.00,mL/min,mL/min,15-20 mg/kg q12h,Sanford Guide 20230414,202304141414,202304141414
IVANC,成人,Clcr,100.00,999.00,mL/min,mL/min,15-20 mg/kg q8-12h,Sanford Guide 20230414,202304141414,202304141414
IVANS,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,End-stage renal disease on intermittent hemodialysis (administer after hemodialysis on dialysis days): Following loading dose of 15 to 25 mg/kg， give either 500 to 1，000 mg or 5 to 10 mg/kg after each dialysis session. Note: Dosing dependent on the assumption of 3 times/week， complete IHD sessions.,[UpToDate on 2020-05-07],202005071143,202005071145
IVANS,成人,eGFR,0,15.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg; 60-80kg:1000mg; 81-100kg:1250mg; >100kg:1500mg.Check a random vancomycin level in 24 hours after the dose. If random level is =<20 mcg/mL， repeat the dose. If random level is >20 mcg/mL， do not redose; repeat random level in 12 hours.,[UpToDate on 2020-05-07],202005071141,202005071142
IVANS,成人,eGFR,15.00,49.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q24H; 60-80kg:1000mg Q24H; 81-100kg:1250mg Q24H; >100kg:1500mg Q24H,[UpToDate on 2020-05-07],202005071138,202303091000
IVANS,成人,eGFR,50.00,90.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q12H; 60-80kg:1000mg Q12H; 81-100kg:1250mg Q12H; >100kg:1000mg Q8H,[UpToDate on 2020-05-07],202005071137,202005071140
IVANS,成人,eGFR,90.00,999.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q8H; 60-80kg:1000mg Q8H; 81-100kg:1250mg Q8H; >100kg:1500mg Q8H,[UpToDate on 2020-05-07],202005071134,202005071139
IVANS,成人,Clcr,0,0,mL/min,mL/min,7.5mg/kg Q2D-Q3D; at end of hemodialysis on dialysis days: next hemodialysis in 1 day: 15mg/kg; 2 day: 25mg/kg; 3days: 35mg/kg,[Sanford Guide - Antimicrobial on 2020-05-07],202005071208,202005071200
IVANS,成人,Clcr,0,10.00,mL/min,mL/min,7.5mg/kg Q2D-Q3D,[Sanford Guide - Antimicrobial on 2020-05-07],202005071202,202005071200
IVANS,成人,Clcr,10.00,100.00,mL/min,mL/min,每日劑量（mg）約為腎絲球濾過率（ml/min）的15倍(穩定狀況下的腎功能),[仿單],,202005071209
IVANS,成人,Clcr,10.00,50.00,mL/min,mL/min,15mg/kg Q24-96h,[Sanford Guide - Antimicrobial on 2020-05-07],202005071201,202005071200
IVANS,成人,Clcr,50.00,120.00,mL/min,mL/min,15mg/KG Q12H,[仿單],,202005071210
IVANS,成人,Clcr,50.00,90.00,mL/min,mL/min,15-30mg/kg Q12h,[Sanford Guide - Antimicrobial on 2020-05-07],202005071200,202005071200
IVC5,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,ESRD (requiring hemodialysis): Adults: IV， Oral: 60 to 100 mg once daily is sufficient to prevent serious ascorbate deficiency due to loss from dialysis; doses >100 mg daily may lead to secondary oxalosis and renal oxalate stone formation.,,201804231727,202303090959
IVEK,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Dialysis: May be administered without regard to timing of dialysis,20231012 Micromedex,202310121055,202310121054
IVEK,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment: No adjustment necessary,20231012 Micromedex,202106091143,202310121055
IVEK,成人,Clcr,0,30.00,mL/min,mL/min,目前無腎功能不全的藥物動力學。不建議用於eGFR<30mL/min。由於賦形劑betadex sulfobutyl ether sodium在腎功能降低時會蓄積，故不建議eGFR<30mL/min使用含有此賦形劑的藥物(如VEKLURY),20231012 仿單,202106091140,202310121121
IVEKS,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment: No adjustment necessary,20231012 Micromedex,202301041111,202310121126
IVEKS,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Dialysis: May be administered without regard to timing of dialysis,20231012 Micromedex,202310121126,202310121126
IVEKS,成人,Clcr,0,30.00,mL/min,mL/min,目前無腎功能不全的藥物動力學。不建議用於eGFR<30mL/min。由於賦形劑betadex sulfobutyl ether sodium在腎功能降低時會蓄積，故不建議eGFR<30mL/min使用含有此賦形劑的藥物(如VEKLURY),Micromedex 20231012 仿單,202301041111,202310121125
IVER,成人,Clcr,0,0,mL/min,mL/min,If repeated IV doses are necessary， give smaller doses and closely monitor PR interval and blood pressure,,201804121510,201804121510
IVFEN,成人,Clcr,0,49.99,mL/min,mL/min,會建議改成口服方式治療(口服不會受腎功能障礙影響),,,202303090959
IVIM,成人,Clcr,0,0,mL/min,mL/min,血液透析可有效清除血漿中的 Lacosamide。4 小時的血液透析治療後，應考慮補充最多 50%的劑量。,仿單,202008031608,202008031607
IVIM,成人,Clcr,0.01,0,mL/min,mL/min,Removed by hemodialysis; after 4-hour hemodialysis treatment， a supplemental dose of up to 50% should be considered.,UpToDate 20200803,202008031615,202008031611
IVIM,成人,Clcr,29.99,0,mL/min,mL/min,CrCl <30 mL/minute: Reduce dose to 75% of the maximum dose.,UpToDate 20200803,202008031610,202008031611
IVIM,成人,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,201912121034,202008031607
IVIM,成人,Clcr,60.00,29.99,mL/min,mL/min,CrCl >=30 mL/minute: No dosage adjustment necessary.,UpToDate 20200803,202008031611,202008031613
IVIM,兒童,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,202008031605,202008031609
IVIR,成人,Clcr,0,10.00,mL/min,mL/min,連續腹膜透析(CAPD)：建議劑量減半(2.5 or 5 mg/kg) Q24H。血液透析：建議劑量減半(2.5 or 5 mg/kg) 每24小時及透析後各使用一次。,仿單 20240502,202405021606,202405021606
IVIR,成人,Clcr,10.00,25.00,mL/min,mL/min,建議劑量(5 or 10mg/kg) Q24H,仿單 20240502,202405021603,202405021603
IVIR,成人,Clcr,25.00,50.00,mL/min,mL/min,建議劑量(5 or 10mg/kg) Q12H,仿單 20240502,202405021603,202405021603
IVOR,成人,Clcr,0,30.00,mL/min,mL/min,Moderate to severe impairment: Use is not recommended; contraindicated in patients in the perioperative period and who are at risk for volume depletion.,,201912091140,201912091140
IWINB,成人,Clcr,0,120.00,mL/min,mL/min,腎衰竭病人不需調整劑量。在這些病人中，cisatracurium注射劑的藥效學數據類似於正常腎功能病人所觀察到的結果，但藥效的開始會稍有延後。,仿單 20240718,202407181739,202407181739
IXOL,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling.,,201804191020,202303090959
IXOL0,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling.,,201804191019,202303091002
IXYL2V,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能患者會因代謝遲緩而引起血漿中濃度上升，故謹慎使用之,,201804191548,201804191548
IZOV,成人,Clcr,0,9.99,mL/min,mL/min,50%正常劑量，給藥間隔24小時,,,202303091000
IZOV,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:an additional dose is recommended after each dialysis,,,202303091001
IZOV,成人,Clcr,10.00,25.00,mL/min,mL/min,正常劑量，給藥間隔24小時,,,202303090959
IZOV,成人,Clcr,26.00,50.00,mL/min,mL/min,正常劑量，給藥間隔12小時,,,202303090959
LAMO5,兒童,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Mild to moderate infection(based on 25-50mg/kg/day，Q8H): 8-20mg/kg/dose，Q24H. Severe infection or high dose(based on 80-90mg/kg/day，Q12H): 20mg/kg/dose，Q24H; do not use the 875mg tablet.,Lexicomp(UpToDate). 2022/10/12,202210121531,202210121534
LAMO5,兒童,eGFR,10.00,29.00,mL/min/1.73m2,mL/min/1.73m2,Mild to moderate infection(based on 25-50mg/kg/day，Q8H): 8-20mg/kg/dose，Q12H. Severe infection or high dose(based on 80-90mg/kg/day，Q12H): 20mg/kg/dose，Q12H; do not use the 875mg tablet.,Lexicomp(UpToDate). 2022/10/12,202210121524,202210121534
LAMO6,成人,eGFR,0,10.00,mL/min,mL/min,GFR <10 mL/min: 250 to 500 mg every 24 hours,Lexi-Drugs. Lexicomp.,201803261606,202004021622
LAMO6,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261607,202004021622
LAMO6,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261606,202004021622
LAUG3,兒童,eGFR,0.01,29.99,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201803261610,201803261610
LAZI,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,須謹慎使用,仿單,202210061458,202210131504
LAZI,成人,eGFR,10.00,80.00,mL/min/1.73m2,mL/min/1.73m2,無須調整劑量,仿單,202210061458,202210131504
LBIS,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191043,202303091000
LCAR,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120035,201804120035
LCEF,成人,Clcr,0,10.00,mL/min,mL/min,creatinine clearance less than 10 mL/minute， 50% of the normal dose,Micromedex 20210105,202101051508,202303091000
LCEF,成人,Clcr,10.00,50.00,mL/min,mL/min,creatinine clearance 10 to 50 mL/minute， 50% to 100% of the normal dose,Micromedex 20210105,202101051507,202303091000
LCET,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Intermittent hemodialysis: 5 mg once daily; 5 mg 3 times per week may also be effective.,,201804231454,202303091001
LCET,成人,eGFR,0,49.90,mL/min/1.73m2,mL/min/1.73m2,5 mg once daily,,201804231453,202303091000
LCET,兒童,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不全的患者服用本藥時，其劑量應減半,,201804250002,201804250002
LCLO,兒童,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,明顯腎功能損害者禁用,[仿單],202006161022,202006161022
LCOFS,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191045,202303091000
LCUR,兒童,Clcr,0,9.99,mL/min,mL/min,For children with renal failure >=40 kg and receiving the adult dosage: 250 or 500 mg amoxicillin/125 mg clavulanic acid q24h.,Micromedex 20231220,202312201230,202312201226
LCUR,兒童,Clcr,0,0.10,mL/min,mL/min,No renal dosing adjustments are available from the manufacturer for children with renal failure,Micromedex 20231220,202312201226,202312201226
LCUR,兒童,Clcr,10.00,30.00,mL/min,mL/min,For children with renal failure >=40 kg and receiving the adult dosage: 250-500 mg amoxicillin/125 mg clavulanic acid q12h,Micromedex 20231220,202312201230,202312201226
LFUL,成人,Scr,0,1.05,mg/dL,mg/dL,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021207,201804021206
LFUL,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021206,201804021206
LFUL,成人,Clcr,0,50.00,mL/min,mL/min,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021207,201804021206
LFUM,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,Acute renal failure: Doses up to 1 to 3 g daily may be necessary to initiate desired response; avoid use in oliguric states. Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.,,201807261507,201807261509
LIBU,成人,Clcr,0,1.00,mL/min,mL/min,嚴重腎衰竭禁用。,仿單 20241115,202411151224,202411151224
LIDO1,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.(KDIGO 2012 guidelines),,201912091124,201912091123
LIDO1,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use in patients with intercurrent disease that increases risk of acute kidney injury.(KDIGO 2012 guidelines),,201912091123,201912091123
LKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg orally every 12 hours,,201804160418,201804160418
LKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg orally every 12 hours,,201804160417,202303090959
LKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg orally every 12 hours,,201804160417,202303091001
LKID,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231416,201804231416
LMEP6,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191043,202303091000
LMUS2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191015,202303091000
LOSTA,成人,Clcr,0,10.00,mL/min,mL/min,[no H/D] Treatment， prophylaxis: use not recommended,仿單 20230922,202311021409,
LOSTA,成人,Clcr,0,9.99,mL/min,mL/min,[Hemodialysis] Treatment: 30mg immediately， then 30mg after every HD cycle Prophylaxis: 30mg immediately， then 30mg after alternate HD cycles [CAPD] Treatment: 30mg (single dose) administered immediately Prophylaxis: 30mg immediately， then 30mg every week,仿單 20230922,202311021410,202311021410
LOSTA,成人,Clcr,10.00,30.00,mL/min,mL/min,Treatment: 30mg qd x 5days Prophylaxis: 30mg q48h,仿單 20230922,202311021409,
LOSTA,成人,Clcr,30.00,60.00,mL/min,mL/min,Treatment: 30mg bid x 5days Prophylaxis: 30mg qd,仿單 20230922,202311021408,
LOSTAS,成人,Clcr,0,10.00,mL/min,mL/min,[no H/D] Treatment， prophylaxis: use not recommended,仿單 20230922,202309221603,202309221603
LOSTAS,成人,Clcr,0,9.99,mL/min,mL/min,[Hemodialysis] Treatment: 30mg immediately， then 30mg after every HD cycle Prophylaxis: 30mg immediately， then 30mg after alternate HD cycles [CAPD] Treatment: 30mg (single dose) administered immediately Prophylaxis: 30mg immediately， then 30mg every week,仿單 20230922,202309221554,202309221604
LOSTAS,成人,Clcr,10.00,30.00,mL/min,mL/min,Treatment: 30mg qd x 5days Prophylaxis: 30mg q48h,仿單 20230922,202309221554,202309221604
LOSTAS,成人,Clcr,30.00,60.00,mL/min,mL/min,Treatment: 30mg bid x 5days Prophylaxis: 30mg qd,仿單 20230922,202309221554,202309221605
LPIR,成人,Clcr,0,20.00,mL/min,mL/min,禁用,,201804160611,201804160611
LPIR,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,,201804160611,202303091001
LPIR,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,,201804160611,202303091001
LPIR,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,,201804160610,202303090959
LRIS,成人,Clcr,0,30.00,mL/min,mL/min,Initial， 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day， with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,,201804142348,201804142348
LSEC,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191047,202303091000
LSLI,成人,Clcr,60.00,0,mL/min,mL/min,Do not use in patients with kidney diseases.,仿單 20230323,202303231208,202303231208
LSOO,兒童,eGFR,0,9.90,mL/min/1.73m2,mL/min/1.73m2,Standard-dose regimens (20-40 mg amoxicillin/kg/day divided q8h OR 25-45 mg amoxicillin/kg/day divided q12h): 8-20 mg amoxicillin/kg/dose q24h. High-dose regimens (80-90 mg amoxicillin/kg/day divided q12h): 20 mg amoxicillin/kg/dose q24h.,Lexicomp 20240311,202403111459,202403111505
LSOO,兒童,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid the 875 mg immediate-release tablets and extended-release tablets.,Lexicomp 20240311,202403111448,202403111448
LSOO,兒童,eGFR,0,1.00,mL/min/1.73m2,mL/min/1.73m2,Hemodialysis: 8-20 mg amoxicillin/kg/dose q24h; give after dialysis. Peritoneal dialysis: 8-20 mg amoxicillin/kg/dose q24h.,Lexicomp 20240311,202403111504,202403111504
LSOO,兒童,eGFR,10.00,29.90,mL/min/1.73m2,mL/min/1.73m2,Standard-dose regimens (20-40 mg amoxicillin/kg/day divided q8h OR 25-45 mg amoxicillin/kg/day divided q12h): 8-20 mg amoxicillin/kg/dose q12h. High-dose regimens (80-90 mg amoxicillin/kg/day divided q12h): 20 mg amoxicillin/kg/dose q12h.,Lexicomp 20240311,202403111452,202403111506
LSUL,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,202303090959
LSUL,成人,Clcr,15.00,30.00,mL/min,mL/min,one-half the usual dose,,,202303090959
LSUR,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191017,202303091000
LTRIL,成人,Clcr,0,30.00,mL/min,mL/min,治療劑量應為一般起始劑量應為一半(每天300mg)，再逐漸增加劑量以達到理想的臨床效果,,201804160419,201804160423
LULE,成人,Clcr,1.00,4.00,mL/min,mL/min,250mg every 48 or 60 hours,,201803261651,201803261650
LULE,成人,Clcr,5.00,14.00,mL/min,mL/min,250mg every 24 hours,,201803261650,201803261650
LULE,成人,Clcr,15.00,29.00,mL/min,mL/min,250mg every 8 or 12 hours,,201803261650,201803261650
LULE,成人,Clcr,30.00,59.00,mL/min,mL/min,不需調整,上限1g/day,201803261650,201803261650
LWEM,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全患者，建議依照腎功能受損程度調整給藥間隔為一天1~2次,,201804141441,201804141441
LZIT,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,,202303090959
LZIT,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,,202303090958
OACAM,成人,Clcr,0,30.00,mL/min,mL/min,CrCl 30 mL/min or less， not recommended,,202002181022,202303091000
OACAM,成人,Clcr,30.00,50.00,mL/min,mL/min,CrCl between 30-50 mL/min， 333 mg ORALLY 3 times daily,,202002181022,202303091001
OACC6,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's.,,201804191048,202303091000
OACE5,成人,Clcr,0,15.00,mL/min,mL/min,2.5 mg on the day of dialysis.,,201811291448,201811291447
OACE5,成人,Clcr,15.01,29.99,mL/min,mL/min,2.5 mg every other day.,,201804121556,201811291447
OACE5,成人,Clcr,30.00,60.00,mL/min,mL/min,2.5 mg per day.,,201804121557,201811291445
OACET,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804121428,201804121428
OACET,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 12 hours,,201804121428,202303090958
OACET,成人,eGFR,50.00,0,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 6 hours,,201804121428,202303090958
OACH,成人,eGFR,10.00,0,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Increase dosing interval to every 8 hours for adults and children,Micromedex20200923,202009230906,202009230908
OACH,成人,eGFR,50.00,10.00,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Adult， increase dosing interval to every 6 hours,Micromedex20200923,202009230907,202009230908
OACH,兒童,eGFR,10.00,0,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Increase dosing interval to every 8 hours for adults and children,Micromedex20200923,202009230906,202009230908
OACH,兒童,eGFR,50.00,10.00,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: pediatric， give usual weight- or age-based dose,Micromedex20200923,202009230907,202009230909
OAGT,成人,Clcr,0,30.00,mL/min,mL/min,禁止使用於重度腎功能不全病人。,仿單,202206271428,202303091001
OAGT,成人,Clcr,30.00,50.00,mL/min,mL/min,建議起始劑量為每日三次，每次服用一錠333毫克藥錠。,仿單,202206271427,202303091001
OAKY,成人,eGFR,1.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， severe or ESRD: Avoid use,Micromedex 20201007,202010071059,202303091000
OALL6,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Recommended dose every 24 hours.,,201804231500,202303091000
OALL6,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Intermittent hemodialysis or peritoneal dialysis: Recommended dose every 24 hours.,,201804231510,202303091002
OALL6,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Recommended dose every 12 to 24 hours.,,201804231500,202303091001
OAMA,成人,Clcr,0,0,mL/min,mL/min,腎功能損傷者及血液透析患者，建議起始劑量為1mg/天,,201804111613,201804112332
OAMIZ,成人,Clcr,0,0,mL/min,mL/min,閉尿.急性腎衰竭.嚴重進行性腎病患不建議使用(仿單),,201804121432,202311271606
OAMO2,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261626,202004021620
OAMO2,成人,eGFR,0.01,10.00,mL/min,mL/min,GFR <10 mL/min: 250 to 500 mg every 24 hours,Lexi-Drugs. Lexicomp,201803261626,202004021620
OAMO2,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp,201803261625,202004021621
OAMO5,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261626,202004021619
OAMO5,成人,eGFR,0.01,10.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261626,202004021618
OAMO5,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261625,202004021620
OAMOX,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,250 mg or 500 mg every 24 hours， depending on severity of infection; give additional dose both during and at the end of dialysis,血液透析患者,202003200914,202303091000
OAMOX,成人,eGFR,0.01,10.00,mL/min/1.73m2,mL/min/1.73m2,250-500mg every 24 hours,,202003200914,202303091000
OAMOX,成人,eGFR,10.00,30.00,mL/min/1.73m2,mL/min/1.73m2,250-500mg every 12 hours,,202003200914,202303091002
OAMT,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能不好避免使用，Benazepril起始劑量5mg，年老虛弱者，Amlodipine起始劑量2.5mg。,,202311271617,202311271619
OANS,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804111625,201804111625
OAPA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Hyperglycemia in patients with Cushing syndrome: Maximum dose: 600 mg once daily,,201806141726,202303091000
OAPR2,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不佳劑量需降低。,,202311281926,202311281926
OAPR5,成人,Clcr,0,0,mL/min,mL/min,腎功能受損的病人，劑量需要減低,,201804121535,201804121536
OARC,成人,Clcr,0,29.99,mL/min,mL/min,不建議使用。,仿單 20240829,201804141616,202408291529
OARH1,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,Moderate to severe impairment: Use is contraindicated.,,201804231652,202303090959
OARIM,成人,Clcr,0,60.00,mL/min,mL/min,Renal impairment: No dosage adjustment necessary,Micromedex 20210504,202105040928,202105040931
OARIM,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎臟損傷病患(creatinine廓清率小於30)禁忌使用,仿單,202105040930,202105040925
OASP,成人,Clcr,0,9.90,mL/min,mL/min,The manufacturer recommends avoiding in patients with CrCl <10 mL/minute.,,201804191222,202303091002
OASV,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's,,201804191049,202303091001
OASZ,成人,Clcr,0,60.00,mL/min,mL/min,腎功能不全者可能增加毒性。建議使用建議劑量範圍中的較低劑量並隨時監測血液反應。如引起血液毒性，劑量應再降低。,仿單 20230724,202307241227,202307241228
OAUG1,成人,Clcr,0,9.99,mL/min,mL/min,usual dose every 24 hours,,201803261630,202303090958
OAUG1,成人,Clcr,10.00,30.00,mL/min,mL/min,usual dose every 12 hours,,201803261629,202303090958
OAZI,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,202001221143,202303090959
OAZI,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,202001221144,202303090959
OBAC5,成人,Clcr,0,30.00,mL/min,mL/min,Reduce dose by 2/3,,201804160522,201804160522
OBAC5,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose by 1/2,,201804160522,201804160522
OBAC5,成人,Clcr,50.00,80.00,mL/min,mL/min,Reduce dose by 1/3,,201804160521,202303091001
OBAR,成人,Clcr,10.00,0,mL/min,mL/min,Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis,UpToDate,202004021451,202004021457
OBAR,成人,Clcr,29.00,10.00,mL/min,mL/min,Administer 30% of usual dose daily or administer the normal dose every 72 hours,UpToDate,202004021451,202004021457
OBAR,成人,Clcr,49.00,30.00,mL/min,mL/min,Administer 50% of usual dose daily or administer the normal dose every 48 hours,UpToDate,202004021452,202004021457
OBAR1,成人,Clcr,10.00,0,mL/min,mL/min,Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis,UpToDate,202004021455,202004021457
OBAR1,成人,Clcr,29.00,10.00,mL/min,mL/min,Administer 30% of usual dose daily or administer the normal dose every 72 hours,UpToDate,202004021456,202004021457
OBAR1,成人,Clcr,49.00,30.00,mL/min,mL/min,Administer 50% of usual dose daily or administer the normal dose every 48 hours,UpToDate,202004021456,202004021457
OBECA,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:0.05 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 7 days; lamivudine-refractory or decompensated liver disease， 0.1 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 7 days; on hemodialysis days， administer after hemodialysis.,,,202303091000
OBECA,成人,Clcr,0,9.99,mL/min,mL/min,0.05 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 7 days; lamivudine-refractory or decompensated liver disease， 0.1 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 7 days.,,,202303091000
OBECA,成人,Clcr,10.00,29.99,mL/min,mL/min,0.15 mg ORALLY once daily (preferred) or 0.5 mg ORALLY every 72 hours; lamivudine-refractory or decompensated liver disease， 0.3 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 72 hours.,,,202303091001
OBECA,成人,Clcr,30.00,49.99,mL/min,mL/min,0.25 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 48 hours; lamivudine-refractory or decompensated liver disease， 0.5 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 48 hours.,,,202303091002
OBEF,成人,Clcr,0,0.01,mL/min,mL/min,Hemodialysis， intermittent (thrice weekly)， Peritoneal dialysis: Avoid use.  If baclofen use cannot be avoided， use lower initial doses and increase gradually as needed and tolerated; initial， 2.5 mg BID and may increase to 5 mg BID as tolerated,Lexidrug 20240410,202404101559,202404101611
OBEF,成人,Clcr,0.01,29.99,mL/min,mL/min,Avoid use. If baclofen use cannot be avoided， initiate at a low dose (2.5 mg Q12H or less); titrate with extreme caution to effect; do not exceed 20 mg/day or ~33% of the usual maximum daily dose， whichever is less. Reduce dose by two-thirds.,Lexidrug/Micromedex 20240410,202404101556,202404101608
OBEF,成人,Clcr,30.00,49.99,mL/min,mL/min,2.5 mg Q8H; titrate cautiously to effect; do not exceed 40 mg/day or ~50% of the usual maximum daily dose， whichever is less. Reduce dose by one-half.,Lexidrug/Micromedex 20240410,202404101555,202404101608
OBEF,成人,Clcr,50.00,80.00,mL/min,mL/min,5mg Q12H; titrate cautiously to effect; do not exceed 50 mg/day or ~66% of the usual maximum daily dose， whichever is less.  Reduce dose by one-third.,Lexidrug/Micromedex 20240410,202404101554,202404101607
OBET2,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全病患每日劑量不可超過 25mg 一天一次,,201804212243,201804212243
OBET2,成人,Clcr,0,15.00,mL/min,mL/min,末期腎病的患者不建議使用,,201804212245,201804212245
OBET2,成人,Clcr,15.00,29.00,mL/min,mL/min,重度腎功能不全病患每日劑量不可超過 25mg 一天一次,,201804212243,202303091001
OBET5,成人,eGFR,0,15.00,mL/min/1.73m2,mL/min/1.73m2,不建議Betmiga使用於末期腎病的病人,仿單,202109271457,202109271456
OBET5,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,每日劑量不可超過25 mg一天一次。,仿單,202109271456,202109271456
OBET5,成人,Clcr,0,15.00,mL/min,mL/min,不建議Betmiga使用於末期腎病的病人,仿單,202109271455,202109271456
OBET5,成人,Clcr,15.00,29.00,mL/min,mL/min,每日劑量不可超過25 mg一天一次。,仿單,202109271455,202303091001
OBIN,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804120000,201804120000
OBLO,成人,Clcr,0,15.00,mL/min,mL/min,對於重度或末期腎功能不全者(肌酸酐廓清率＜15mL/min)之臨床使用經驗有限。對於這些病患， 應該根據觀察血壓的監測小心逐次調整劑量。,仿單,202011130831,202011130834
OBLO,成人,Clcr,15.00,60.00,mL/min,mL/min,對於腎功能不全者，包括正在進行血液透析的患者，起始劑量為4mg，再根據患者反應逐次調整劑量。,仿單,202011130835,202011130834
OBMZ,成人,Clcr,0,0,mL/min,mL/min,Renal impairment: initiate therapy at a very low dose,Micromedex 20230209,202302091749,202302091749
OBOK,成人,Clcr,0,9.90,mL/min,mL/min,The manufacturer recommends avoiding in patients with CrCl <10 mL/minute.,,201804191223,202303090959
OBONE,成人,Clcr,0,30.00,mL/min,mL/min,每天800mg,,201804120002,201804120002
OBONE,成人,Clcr,30.00,50.00,mL/min,mL/min,每天1200mg,,201804120002,202303091000
OBONE,成人,Clcr,50.00,80.00,mL/min,mL/min,每天1600mg,,201804120001,202303091001
OBOW,成人,Clcr,0,30.00,mL/min,mL/min,腎功能嚴重下降患者不建議使用,,201804131641,201804131641
OBRO,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全者不建議使用,,201804191414,201804191414
OBUSR,成人,Clcr,0,0,mL/min,mL/min,腎功能不全且無尿患者建議Reduce dose by 25% to 50%,嚴重腎功能不全者不建議使用,201804150016,201804150017
OCAL5,成人,Clcr,0,24.99,mL/min,mL/min,Dosage adjustments may be necessary depending on the serum calcium levels.,,201804231741,201804231741
OCAN,成人,eGFR,0,15.00,mL/min/1.73m2,mL/min/1.73m2,Contraindications: severe renal impairment， end-stage renal disease or patients on dialysis.,仿單&Micromedex建議,201907091101,202312061658
OCAN,成人,eGFR,15.00,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,仿單建議,201907290913,202312061656
OCAND8,成人,Clcr,0,15.00,mL/min,mL/min,對於非常嚴重或者是末期的腎臟功能不良者 ( 肌酸酐廓清率Clcreatinine<15 mL/min)，臨床使用經驗有限,仿單,202011231047,202011130834
OCAND8,成人,Clcr,15.00,59.99,mL/min,mL/min,Renal impairment， adult (moderate to severe， CrCl 15 to 60 mL/min/1.73 m(2)): 8 mg daily may be a sufficient dose,Micromedex 20201123,202011231040,202011231048
OCAND8,成人,Clcr,15.00,60.00,mL/min,mL/min,對於腎功能不全者，包括正在進行血液透析的患者，起始劑量為4mg，再根據患者反應逐次調整劑量。,仿單,202011130850,202011130834
OCAND8,兒童,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， pediatric (GFR less than 30 mL/min/1.73 m(2)): Use not recommended,Micromedex 20201123,202011231140,202011231048
OCAP5,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201803191622,202303090941
OCAP5,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose to 75% of usual dose,,201803191621,202303090940
OCAR1,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不良，使用本藥需較低劑量。,,202311281944,
OCARD4,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不良，使用本藥需較低劑量。,,202311281945,
OCAT,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病人依病患降壓反應調整劑量，需小心監策測,,201804130627,201804130627
OCAT2,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091133,201912091133
OCEFA,成人,Clcr,0,9.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg Q36H,Ref: Lexicomp Accessed: 2020-05-03,,202005030956
OCEFA,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 1g then 1g AD CAPD: 500 mg q24h CRRT: No data,Ref: Sanford Guide Web Ed. Accessed: 2020-05-03,,202005030959
OCEFA,成人,Clcr,10.00,24.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg QD,Ref: Lexicomp Accessed: 2020-05-03,,202005030955
OCEFA,成人,Clcr,25.00,49.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg Q12H,Ref: Lexicomp Accessed: 2020-05-03,,202005030955
OCEL2,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙病患不建議使用,,201804141619,201804141619
OCEPH,成人,Clcr,5.00,14.00,mL/min,mL/min,250mg every 24 hours,,,202303090958
OCEPH,成人,Clcr,15.00,29.00,mL/min,mL/min,250mg every 8 or 12 hours,,,202303090958
OCEPH,成人,Clcr,30.00,59.00,mL/min,mL/min,無須調整劑量,1g/day,,202303090958
OCEPO,成人,Clcr,0,0,mL/min,mL/min,藥物代謝會減低，在達到預期之治療效果後，服藥間隔宜加大或劑量宜減低,若同時須使用利尿劑建議loop diuretic，而非thiazide-type diuretic,201804121544,202303091000
OCER4,成人,Clcr,0,30.00,mL/min,mL/min,Reduce the dosage to 400 mg orally once daily,,201804130653,201804130703
OCEX,成人,eGFR,0,20.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50%,Severe impairment & Anuric(eg， GFR <10 to 20 mL/minute/1.73 m2): Reduce dose by 50%,201909031537,201909031541
OCHA1,成人,Clcr,0,30.00,mL/min,mL/min,建議起始劑量為每日一次0.5 mg，患者接著可以視需求調整到最大劑量每日兩次0.5mg,血液透析病患若對本藥耐受性良好，可以使用最大劑量每日一次0.5mg,201804191509,201804191514
OCHA5,成人,Clcr,0,30.00,mL/min,mL/min,建議起始劑量為每日一次0.5 mg，患者接著可以視需求調整到最大劑量每日兩次0.5mg,血液透析病患若對本藥耐受性良好，可以使用最大劑量每日一次0.5mg,201804191515,201804191515
OCHE,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,202303090959
OCHE,成人,Clcr,15.00,30.00,mL/min,mL/min,one-half the usual dose,,,202303090959
OCIA5,成人,Clcr,0,30.00,mL/min,mL/min,for erectile dysfunction: as-needed use， MAX dose is5 mg ORALLY; do not repeat more frequently than once every 72 hours,for benign prostatic hyperplasia:once daily use， not recommended,201804192053,201804192057
OCIA5,成人,Clcr,30.00,50.00,mL/min,mL/min,for erectile dysfunction: 5 mg ORALLY once daily， MAX dose is 10 mg ORALLY not more frequently than once every 48 hours,for benign prostatic hyperplasia:2.5 mg ORALLY once daily; may increase to 5 mg ORALLY once daily,201804192055,201804192056
OCINO,成人,Clcr,0,30.00,mL/min,mL/min,MAX DOSE: 500mg/day,,201905220955,201905220955
OCINO,成人,Clcr,4.99,0,mL/min,mL/min,Hemodialysis (Give AD on dialysis days) Oral: 250-500mg q24h IV: 200-400mg q24h,Sanford Guide 20230323,202303231404,202303231405
OCINO,成人,Clcr,29.00,5.00,mL/min,mL/min,Oral: 500-750mg q24h IV: 200-400mg q18-24h,Sanford Guide 20230323,202303231404,202303231406
OCINO,成人,Clcr,30.00,60.00,mL/min,mL/min,MAX DOSE: 1000mg/day,,201905220955,202303091002
OCINO,成人,Clcr,50.00,30.00,mL/min,mL/min,Oral: 250-500mg q12h IV: 200-400mg q8-12h,Sanford Guide 20230323,202303231403,202303231406
OCIPR,成人,Scr,1.40,1.90,mg/dL,mg/dL,1000 mg/day,,,202303090959
OCIPR,成人,Scr,2.00,10.00,mg/dL,mg/dL,500mg/day,,,202303090959
OCIZO,成人,Clcr,0,50.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution.,,202003121624,202303091000
OCOD,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,嚴重腎功能障礙病患建議使用loop diuretics效果，會較thiazide來的好,201804121609,201804121609
OCODI,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,50% of normal dose,,201804141528,201804141528
OCODI,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,75% of normal dose,,201804141528,201804141528
OCOLC,成人,Clcr,0,30.00,mL/min,mL/min,0.3 mg/day orally initially; increase dose with adequate monitoring,Do not repeat course more than once every 2 weeks(gout),201804142307,201804142307
OCOMP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231418,201804231418
OCON,成人,Clcr,0,20.00,mL/min,mL/min,建議初始劑量: 2.5 mg ORALLY once daily,最高劑量:10 mg ORALLY once daily,201804121446,201804121446
OCON1,成人,Clcr,0,20.00,mL/min,mL/min,建議初始劑量: 2.5 mg ORALLY once daily,最高劑量:10 mg ORALLY once daily,201804121448,201804121448
OCONI,成人,Clcr,10.00,0,mL/min,mL/min,不建議使用於嚴重腎功能不全患者(CLCR <10 ml/min),[仿單],201912181529,202303091001
OCONT,成人,Clcr,0,0,mL/min,mL/min,末期腎病變不建議使用,[仿單],202312061854,
OCONT,成人,Clcr,0,60.00,mL/min,mL/min,中度到重度腎功能不全，每日最高劑量兩顆。,[仿單],202312061853,
OCOP,成人,Clcr,0,29.99,mL/min,mL/min,Contraindication.,,201812250937,201812250938
OCOR5,成人,Clcr,0,15.00,mL/min,mL/min,應謹慎使用,,201804120042,201804120042
OCRA5,成人,Clcr,0,10.00,mL/min,mL/min,(包含血液透析及腹膜透析) 原給藥方式:500mg Q12H:首次劑量500mg，之後125mg Q24H;  原給藥方式:500mg Q24H:首次劑量500mg，之後125mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q48H;,仿單,202112141058,202112141051
OCRA5,成人,Clcr,10.00,19.00,mL/min,mL/min,if normal adult dose is 750 mg every 24 hours change to 750 mg initially then 500 mg every 48 hours; 500 mg every 24 hours change to 500 mg initially then 250 mg every 48 hours; 250 mg every 24 hours change to 250 mg every 48 hours (no dose adjustment necessary if treating uncomplicated UTI).,Micromedexs 20211214,202112141042,202112141050
OCRA5,成人,Clcr,10.01,19.00,mL/min,mL/min,原給藥方式:500mg Q12H:首次劑量500mg，之後125mg Q12H;  原給藥方式:500mg Q24H:首次劑量500mg，之後125mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q48H;,仿單,202112141056,202112141051
OCRA5,成人,Clcr,20.00,49.00,mL/min,mL/min,if normal adult dose is 750 mg every 24 hours change to every 48 hours; 500 mg every 24 hours change to 500 mg initially then 250 mg every 24 hours; 250 mg every 24 hours is no adjustment necessary.,Micromedexs 20211214,202112141036,202303091002
OCRA5,成人,Clcr,20.00,50.00,mL/min,mL/min,原給藥方式:500mg Q12H:首次劑量500mg，之後250mg Q12H;  原給藥方式:500mg Q24H:首次劑量500mg，之後250mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q24H;,仿單,,202112141051
OCRE,成人,Clcr,0,30.00,mL/min,mL/min,起始劑量:5 mg orally once daily,最高劑量:10 mg orally once daily,201804130712,201804130712
OCRE2,成人,eGFR,0,29.90,mL/min/1.73m2,mL/min/1.73m2,(重度腎功能不全 (CLcr<30 mL/min/1.73 m2) 未接受血液透析) 以 5mg QD 開始治療，不可超過 10mg QD。,仿單 20240704,202407041203,202407041204
OCRET,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全且未接受血液透析者，劑量不可超過10/10毫克每日一次。,仿單 20231222,202312221031,202312221031
OCUR,成人,Clcr,29.99,0,mL/min,mL/min,本藥只能用於腎絲球過濾率大於30毫升/分鐘的病患,仿單,202007290942,202307210942
OCUR,成人,Clcr,30.00,0,mL/min,mL/min,The extended-release (1000mg amoxicillin/tablet) and 875-mg tablets should not be used in patients with a CrCl <30 mL/min,Moicromedex 20230717,202307171211,202307171214
OCUR,成人,Clcr,999.00,30.00,mL/min,mL/min,1000mg Q12H,仿單,202307171215,202307210945
OCYM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804150044,201804150044
ODEF,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙病患建議劑量為 300 mg every 12 hours，增加劑量時須謹慎小心,,201804131623,201804131623
ODEN,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Mild to severe impairment: 5 mg every other day.,,201804231512,202303091000
ODEPY,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,202003201157,202303091000
ODEPY,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer every 6 hours.,,202003201157,202303090959
ODEPY,兒童,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,202003201158,202303091001
ODET,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率每分鐘小於或等於30 毫升病患的建議劑量是每次1 毫克、一天二次,仿單,202210171133,202210171433
ODET4,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全患者建議劑量是每次2毫克、一天一次,,201804212256,201804212256
ODIBO,成人,Scr,2.00,99.99,mg/dL,mg/dL,Serum creatinine >2 mg/dL or CrCl <25 ml/minute/1.73 m2: Use is not recommended; systemic AUC increased 6-fold in patients with CrCl <25 mL/ minute/1.73 m2.,,201810261032,201810261032
ODIBO,成人,Clcr,0,25.00,mL/min,mL/min,不建議使用,[仿單],202312061858,201810261032
ODIC1,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091134,201912091134
ODIF,成人,Clcr,0,10.00,mL/min,mL/min,Give initial loading dose of 50 to 400 mg， followed by the usual dosage after each hemodialysis session and 50% of the usual dose on nondialysis days if CrCl is 50 mL/min or less.,,,202303091000
ODIF,成人,Clcr,10.00,20.00,mL/min,mL/min,給藥間隔72小時或正常每日劑量的三分之一,,,202303090959
ODIF,成人,Clcr,21.00,40.00,mL/min,mL/min,給藥間隔48小時或正常每日劑量的一半,,,202303090959
ODIG,成人,Scr,0,0,mg/dL,mg/dL,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120036,202003131035
ODIG,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 48 hours,(10% to 25% of the usual dose every 48 hours),202003131030,202003131031
ODIG,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 24 to 36 hours,(25% to 75% of the usual dose every 24 to 36 hours),202003131030,202003131032
ODIG,成人,eGFR,50.00,999.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] No dosage adjustment necessary.,,202003131031,202003131030
ODIG,成人,Clcr,0,30.00,mL/min,mL/min,[UpToDate] 0.125 mg every 48 hours,,202003131033,202003131031
ODIG,成人,Clcr,30.00,80.00,mL/min,mL/min,[UpToDate] 0.125 mg once daily,,202003131033,202003131031
ODIG,成人,Clcr,80.00,120.00,mL/min,mL/min,[UpToDate] Alternate between doses of 0.25 mg and 0.125 mg once daily,,202003131033,202003131031
ODIG,成人,Clcr,120.00,999.00,mL/min,mL/min,[UpToDate] 0.25 mg once daily,,202003131032,202003131031
ODIG2,成人,Scr,0,0,mg/dL,mg/dL,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,202003131034,202003131035
ODIG2,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 48 hours,(10% to 25% of the usual dose every 48 hours),202003131033,202003131031
ODIG2,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 24 to 36 hours,(25% to 75% of the usual dose every 24 to 36 hours),202003131034,202003131032
ODIG2,成人,eGFR,50.00,999.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] No dosage adjustment necessary.,,202003131034,202003131030
ODIG2,成人,Clcr,0,30.00,mL/min,mL/min,[UpToDate] 0.125 mg every 48 hours,,202003131034,202003131031
ODIG2,成人,Clcr,30.00,80.00,mL/min,mL/min,[UpToDate] 0.125 mg once daily,,202003131034,202003131031
ODIG2,成人,Clcr,80.00,120.00,mL/min,mL/min,[UpToDate] Alternate between doses of 0.25 mg and 0.125 mg once daily,,202003131034,202003131031
ODIG2,成人,Clcr,120.00,999.00,mL/min,mL/min,[UpToDate] 0.25 mg once daily,,202003131034,202003131031
ODIP,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全之病患不建議使用(特別是無尿症),,201804160549,201804160549
ODOG5,成人,Clcr,0,10.00,mL/min,mL/min,34% of normal dose,,201804142351,201804142351
ODOG5,成人,Clcr,10.00,30.00,mL/min,mL/min,50% of normal dose,,201804142351,202303090959
ODOG5,成人,Clcr,30.00,60.00,mL/min,mL/min,70% of normal dose,,201804142350,202303091000
ODOLC,成人,Clcr,30.00,120.00,mL/min,mL/min,無須調整劑量,,,202303090958
ODOM,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Depending on severity of impairment， frequency should be reduced to 1 to 2 times daily and dosage reduction considered with repeated administration.,,201812281051,202303090959
ODOP,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,202003151140,201806141747
ODOP,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,202003151140,201806141747
ODOP,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,202003151140,201806141747
ODOR4,成人,Clcr,0,0,mL/min,mL/min,因主要副作用為引起浮腫.血壓上升，腎臟疾病患者應注意,,201804231421,202308061053
ODUO,成人,Clcr,0,10.00,mL/min,mL/min,未期腎病患者未進行研究,,201804212309,201804212309
ODUO,成人,Clcr,10.00,30.00,mL/min,mL/min,中度到重度腎功能受損患者無須調整劑量,,201804212309,202303091000
ODUX,成人,Clcr,0.01,29.99,mL/min,mL/min,避免使用於重度腎功能障礙(腎絲球過濾率<30 mL/min)的病患,仿單 20240609,202406091639,202406091649
OEBI,成人,Clcr,5.00,29.00,mL/min,mL/min,reduce dosage to 5 mg ORALLY twice daily,Micromedex 20220209,201804160555,202202091116
OEBI,成人,Clcr,5.00,49.00,mL/min,mL/min,中度受損(Clcr:30-49)及重度受損(Clcr:5-29)患者每日劑量應為10mg,仿單,202202091133,202202091116
OEFE7,成人,eGFR,10.00,70.00,mL/min/1.73m2,mL/min/1.73m2,建議降低25-50%用量開始治療。,血液透析法治療之患者，建議以降低50%之用量開始治療，且等血液透析(四小時)完成後再服用藥物,201804150053,202303091000
OEFI3,成人,Clcr,0,50.00,mL/min,mL/min,No dosage adjustment is necessary for patients with renal impairment; however， there is limited information in patients with end-stage renal disease,,202004021107,202303091000
OELI,成人,Scr,1.50,7.00,mg/dL,mg/dL,血清肌酸酐大於或等於1.5mg/dL，且併有年齡大於等於80歲或體重小於等於60公斤，建議劑量為2.5mg，一天兩次。,仿單,202201251635,202201251637
OELI,成人,Clcr,0,14.99,mL/min,mL/min,Avoid use in severe renal impairment.,仿單,201807011130,202302161158
OELI,成人,Clcr,15.00,29.99,mL/min,mL/min,用於中風預防:2.5 mg twice daily. 用於DVT/PE:謹慎使用。,仿單,201807011129,202302161158
OELI2,成人,Scr,1.50,99.00,mg/dL,mg/dL,血清肌酸酐大於或等於1.5mg/dL、年齡大於等於80歲、體重小於等於60公斤，併有上述其中兩項者，建議劑量 2.5mg BID。,仿單 20240131,202201251640,202401310843
OELI2,成人,Scr,1.50,10.00,mg/dL,mg/dL,DVT/PE: No dosage adjustment is necessary， including patients on dialysis. AF: If age >=80 years and/or weight <=60 kg， 2.5 mg orally twice daily.,Micromedex 20240131,202401311422,202401311423
OELI2,成人,Clcr,0,14.99,mL/min,mL/min,Not recommend to use in severe renal impairment or dialysis.,仿單 20240131,201908071537,202401310840
OELI2,成人,Clcr,15.00,29.99,mL/min,mL/min,用於中風預防: 2.5 mg twice daily. 用於DVT/PE: 謹慎使用。,仿單 20240131,201908071537,202401310838
OEND,成人,Clcr,0,10.00,mL/min,mL/min,嚴重腎功能不全者，則降低50%的劑量,,201804261547,202106181414
OENTR,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,建議起始劑量為每日2次50mg,依患者耐受情況，每2至4周加倍Entresto的劑量，達到每日2次200mg的目標維持劑量,201804130633,201804130633
OENZI,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,201806141747,201806141747
OENZI,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,201806141748,201806141747
OENZI,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,201806141748,201806141747
OEPB,成人,Clcr,0,30.00,mL/min,mL/min,20 to 25 mg/kg orally 3 times per week.,25mg/kg orally 3 times per week,,202303091001
OEPC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,目前尚未針對重度腎功能不全或患有須接受血液透析治療之末期腎病（ESRD）的患者評估過Epclusa的安全性與療效,,201910061123,202303091002
OEPR,成人,Clcr,0,30.00,mL/min,mL/min,Severe impairment: CrCl <30 mL/minute: Use with caution.,,201910061207,202303090959
OERAF,成人,Clcr,0,10.00,mL/min,mL/min,Treatment/Prophylaxis: ESRD not undergoing dialysis: Use is not recommended (has not been studied),,201811211422,201811231050
OERAF,成人,Clcr,10.01,30.00,mL/min,mL/min,Treatment: 30 mg once daily Prophylaxis: 30 mg every other day,,201811211422,201811231050
OERAF,成人,Clcr,30.01,60.00,mL/min,mL/min,Treatment: 30 mg twice daily Prophylaxis: 30 mg once daily,,201811211421,201811231050
OESM,成人,Clcr,0,0,mL/min,mL/min,由於缺乏特定研究，因此ulipristal acetate並不建議使用於嚴重腎功能不全的病患，除非病患接受密切監測,,201804242338,201804242338
OEVO,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者持續維持藥物血中高濃度，而可能提高副作用的發生率,,201804191426,201804191426
OFAM,成人,Clcr,0,9.99,mL/min,mL/min,血液透析病人:"每次洗腎之後應立即投予 famciclovir；帶狀\疹患者:建議劑量為 250 毫克;生殖器\疹患者:125毫克",,,202303091001
OFAM,成人,Clcr,10.00,30.00,mL/min,mL/min,"治療帶狀\疹與初發性之生殖器\疹感染症：每天125毫克，一天三次;治療急性復發之生殖器\疹感染症時，無須調整劑量",,,202303091001
OFAMO,成人,Clcr,0,0,mL/min,mL/min,洗腎患者: 1 次 20mg 洗腎後 1 次,仿單,201909251622,202008031024
OFAMO,成人,Clcr,29.99,0,mL/min,mL/min,If usual dose is 10 mg twice daily or 20 mg once daily: 10 mg every other day; If usual dose is 20 mg twice daily: 10 mg once daily or 20 mg every other day,UpToDate 20200803,202008031028,202008031024
OFAMO,成人,Clcr,30.00,0,mL/min,mL/min,1 次 20mg， 2∼3 日 1 次,仿單,201909251621,202008031024
OFAMO,成人,Clcr,59.99,30.00,mL/min,mL/min,If usual dose is 10 mg twice daily or 20 mg once daily: 10 mg once daily or 20 mg every other day; If usual dose is 20 mg twice daily: 20 mg once daily or 40 mg every other day,UpToDate 20200803,202008031029,202008031024
OFAMO,成人,Clcr,60.00,30.00,mL/min,mL/min,1 次 20mg ，1 日 1 次,仿單,201909251621,202008031024
OFAX,成人,Clcr,0,0,mL/min,mL/min,輕度或中度腎功能不全病患 建議降低 usual dosage by 25% to 50%,血液透析病患 建議Decrease usual dosage by 50%,201804150048,201804150050
OFEB,成人,Clcr,15.00,29.00,mL/min,mL/min,Limit dose to 40 mg once daily,,201804142310,201804142310
OFLU,成人,Scr,2.50,0,mg/dL,mg/dL,應避免使用,,201804120103,201804120104
OFLUC,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's,,201804191057,202303091001
OFOL,成人,Clcr,0,0,mL/min,mL/min,病人若有腹水，胸膜滲透液，腎功能障礙或Hydration不夠時會延遲methotrexate排出，應考慮增加Folina劑量或延長治療時間,若建議劑量高於口服使用許可劑量，應改以靜脈注射給藥,201804191520,201804191520
OFOR,成人,eGFR,0,25.00,mL/min/1.73m2,mL/min/1.73m2,針對此類病人不建議開始治療，然而Forxiga治療後，eGFR降低至小於25 mL/min/1.73 m2的病人，可持續使用以降低eGFR下降、ESKD、心血管死亡和心衰竭住院的風險。,仿單,202109140952,202111301201
OFOR,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,透析病患禁止使用Forxiga.,仿單,202109140957,202111301203
OFOR,成人,eGFR,0,0.01,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (ESRD or dialysis) in any population: Use is contraindicated.,Micromedex 20210914,202109141105,202109141106
OFOR,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,used for glycemic control: Use not recommended. type 2 diabetes when used to reduce risk of hospitalization for heart failure: Insufficient data to support dose adjustment recommendation.,Micromedex 20210914,202109141055,202109141100
OFOR,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,used for glycemic control: Use is contraindicated. heart failure with reduced ejection fraction (with or without type 2 diabetes) when used to reduce risk of cardiovascular death/hospitalization: Insufficient data to support dose adjustment recommendation.,Micromedex 20210914,202109141057,202109141059
OFOR,成人,eGFR,25.00,45.00,mL/min/1.73m2,mL/min/1.73m2,每天口服1次10毫克。,仿單,201804112343,202312061911
OFOR,成人,eGFR,45.00,99.00,mL/min/1.73m2,mL/min/1.73m2,為改善血糖控制，Forxiga的建議起始劑量是5毫克每天口服1次。在耐受Forxiga 5毫克每天1次的病人，需要對於額外血糖控制時，劑量可增至10毫克每天口服1次。對於所有其他適應症的建議起始劑量是每天口服1次10毫克。,仿單,202111301159,202109141054
OFOSP,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804120003,201804120008
OFUCO,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,201804021212,202303091001
OFUCO,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer every 6 hours.,,201804021212,202303090959
OFUCO,兒童,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,201804021213,202303090959
OFUN,成人,Clcr,50.00,0,mL/min,mL/min,穩定且慢性腎功能異常的病人，應使用建議劑量的一半。並應在用藥前後追蹤檢查其肝功能。,[仿單],202110201120,202110201129
OFYC,成人,Clcr,0,0,mL/min,mL/min,中度腎功能不全病患建議:Close monitoring and slower dose titration may be necessary based on patient's response and tolerability,重度腎功能不全病患不建議使用,201804160428,201804160428
OGALM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112345,201804112345
OGLIV,成人,Clcr,0,19.99,mL/min,mL/min,Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment,,201804301513,201804301513
OGLIV,成人,Clcr,20.00,39.99,mL/min,mL/min,Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.,,201804301513,202303091001
OGLIV,成人,Clcr,40.00,59.99,mL/min,mL/min,Maximum recommended dose: 600 mg.,,201804301512,201804301513
OGLUB1,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112338,201804112338
OGLUC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Use is contraindicated,Micromedex 20201006,202010021202,202010061216
OGLUC,成人,eGFR,30.00,45.00,mL/min/1.73m2,mL/min/1.73m2,Use not recommended,Micromedex 20201006,202010061217,202010061216
OGLUC,成人,eGFR,30.01,45.00,mL/min/1.73m2,mL/min/1.73m2,應減量使用,仿單,202010061236,202010061216
OGLUC,成人,eGFR,45.00,45.00,mL/min/1.73m2,mL/min/1.73m2,eGFR falls below 45 mL/min/1.73 m(2) after initiation: Assess benefits and risks of continuing treatment,Micromedex 20201006,202010061217,202010061219
OGLUF,成人,Clcr,0,0,mL/min,mL/min,腎衰竭患者服藥後要務之半衰期延長，可能導致低血糖的副作用，須謹慎使用。,,201804112331,201804112331
OGLUM,成人,Scr,1.40,0,mg/dL,mg/dL,不建議使用,女性,201804112348,201804112348
OGLUM,成人,Scr,1.50,0,mg/dL,mg/dL,不建議使用,男性,201804112347,201804112347
OGOU,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者需應斟酌減低劑量，嚴重腎功能不全者不建議使用,,201804142313,202303091000
OGXB,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,低於30 mL/min/1.73 m2不應使用,[仿單],202007051226,202109011108
OGXB,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， eGFR less than 30 mL/min/1.73 m(2)， including ESRD: Use not recommended,[Micromedex 20210901],202007061544,202109011110
OHAR4,成人,Clcr,0,0.10,mL/min,mL/min,Peritoneal dialysis， Hemodialysis (intermittent， thrice weekly): Unlikely to be dialyzed (highly protein bound): No dosage adjustment likely to be necessary (has not been studied); use with caution.,UpToDate 20240131,202401311406,202401311408
OHAR4,成人,Clcr,0,0,mL/min,mL/min,對腎功能低下者宜由0.1mg 開始投與，經過充分觀察才增量至0.2 mg。由於本藥單位含量較高，因此不建議使用於上述病患。,仿單 20240131,201804212318,202401311402
OHAR4,成人,Clcr,0,9.99,mL/min,mL/min,(ESRD， CrCl<10) No specific recommendations are available.,Micromedex 20240131,202401311403,202401311404
OHAR4,成人,Clcr,0.01,9.99,mL/min,mL/min,No dosage adjustment likely to be necessary (has not been studied); use with caution.,UpToDate 20240131,202401311405,202401311406
OHAR4,成人,Clcr,10.00,999.00,mL/min,mL/min,No dosage adjustment necessary.,Micromedex 20240131,202401311403,202401311402
OHARV,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,無法提供任何劑量建議,,,202303091001
OHYD,成人,Clcr,0,10.00,mL/min,mL/min,Reduce initial dose by 50% (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity,,201804301511,202303091000
OHYD,成人,Clcr,0,60.00,mL/min,mL/min,Reduce initial dose by 50%; titrate to response/avoidance of toxicity,,201804301510,202303091002
OHYXQ,成人,Clcr,50.00,0,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.,,202004071046,202303090959
OIMU,成人,Clcr,0,9.99,mL/min,mL/min,Administer 50% of normal dose.,,201804231640,202303091001
OIMU,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis (partially dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose; supplement: 0.25 mg/kg.,,201804231640,202303090959
OIMU,成人,Clcr,10.00,50.00,mL/min,mL/min,Administer 75% of normal dose.,,201804231639,202303091001
OINDO2,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.,KDIGO 2012 guidelines provide the following recommendations for NSAIDs,201910031032,202303091000
OINDO2,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.,KDIGO 2012 guidelines provide the following recommendations for NSAIDs,201910031032,202303091000
OINV,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804142355,201804142355
OINV,成人,Clcr,10.00,50.00,mL/min,mL/min,起始劑量:1.5 mg once daily,最高劑量:3 mg once daily,201804142355,202303091001
OINV,成人,Clcr,50.00,80.00,mL/min,mL/min,起始劑量:3 mg once daily,最高劑量:6 mg once daily,201804142354,202303091000
OISO2,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病人應謹慎使用(約70%的投與藥物代謝產物由尿液排除),,201804121520,201804121520
OJADU,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Including ESRD: Contraindicated 禁用於重度腎功能不全病人（腎絲球過濾率估計值小於30 mL/min/1.73 m2）,Micromedex 20240327 仿單 20240327,202403271042,202403271049
OJADU,成人,eGFR,30.00,44.99,mL/min/1.73m2,mL/min/1.73m2,Do not initiate treatment with this combination,Micromedex 20240327,202403271043,202403271049
OJADU,成人,eGFR,45.00,59.99,mL/min/1.73m2,mL/min/1.73m2,In patient undergoing iodinated contrast imaging procedure: Discontinue at time of or before procedure; evaluate eGFR 48 hours after imaging procedure; restart if renal function stable.,Micromedex 20240327,202403271043,202403271049
OJAN,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,每日一次25mg,仿單建議,201805301116,202303091001
OJAN,成人,eGFR,30.00,44.99,mL/min/1.73m2,mL/min/1.73m2,每日一次50mg,仿單建議,201805301115,201805301125
OJAR,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112344,201804112344
OJAR2,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe)， ESRD， or receiving dialysis: Use contraindicated.,Micromedex 20200710,201806251352,202007101024
OJAR2,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率估計值低於30mL/min/1.73m2或洗腎的病人不建議使用.,仿單,202007101025,202212011530
OJAR2,成人,eGFR,30.00,99.00,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率估計值大於等於30mL/min/1.73m2的病人無需調整劑量.,仿單,202007101026,202007101025
OJAR2,成人,eGFR,30.00,45.00,mL/min/1.73m2,mL/min/1.73m2,Do not initiate therapy; discontinue use if eGFR drops and remains below 45 mL/min/1.73m(2),Micromedex 20200710,201806251351,202007101023
OJIN1,成人,Clcr,0,10.00,mL/min,mL/min,禁用於無尿症病人。CrCl <10 mL/min， use not recommended.,仿單 20230727,202307271512,202307271512
OJIN4,成人,Clcr,0,10.00,mL/min,mL/min,禁用於無尿症病人。CrCl <10 mL/min， use not recommended.,仿單 20230727,202307271629,202307271629
OKCB,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不全避免使用(仿單),,202311261415,201803191053
OKCB,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Moderate-severe impairment: Avoid use.,,201803191053,201803191053
OKCIT,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者可能會引起高血鉀或鹼中毒症狀，應定期測定血中電解質含量，以避免副作用發生,,201804212343,201804212343
OKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg orally every 12 hours,,201804160414,201804160416
OKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg orally every 12 hours,,201804160414,202303091000
OKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg orally every 12 hours,,201804160413,202303091000
OKET,成人,Clcr,0,30.00,mL/min,mL/min,Advanced impairment or patients at risk for renal failure due to volume depletion: Use is contraindicated.,,201912091114,201912091115
OKIS,成人,eGFR,15.00,29.99,mL/min/1.73m2,mL/min/1.73m2,eGFR 15 to <30 mL/minute/1.73 m2: Reduce initial dose to 200 mg once daily.,,201912230934,202303091001
OKIS0,成人,eGFR,15.00,29.99,mL/min/1.73m2,mL/min/1.73m2,eGFR 15 to <30 mL/minute/1.73 m2: Reduce initial dose to 200 mg once daily.,,202107281639,202303091002
OKLA5,成人,Clcr,0,30.00,mL/min,mL/min,dose should be reduced 50%,,,202303090958
OKLA5X,成人,Clcr,0,30.00,mL/min,mL/min,肌酸酐廓清率低於 30 mL/min之嚴重腎功能不全病人，劑量需減半，一般建議劑量為 250 mg每天一次，因KlaricidXL不可剝半，故不可用於嚴重腎功能不全病人，須改用Klaricid的速放劑型。 在較嚴重的感染建議劑量為250mg每天兩次，這些病人不得連續使用超過14天。,仿單,202211301030,202211301030
OKLA5X,成人,Clcr,0,29.99,mL/min,mL/min,severe renal impairment: CrCl less than 30 mL/min， dose should be reduced 50%,Micromedex 2022/11/30,202211301021,202211301023
OKLAR,成人,Clcr,0,30.00,mL/min,mL/min,In combination with atazanavir or ritonavir:Decrease clarithromycin dose by 75%.,,201807111149,201807111150
OKLAR,成人,Clcr,0,9.99,mL/min,mL/min,Hemodialysis: Administer after HD session is completed.,,201807111147,201807111147
OKLAR,成人,Clcr,0,29.99,mL/min,mL/min,Decrease clarithromycin dose by 50%.,,201807111142,202303091001
OKLAR,成人,Clcr,30.00,60.00,mL/min,mL/min,In combination with atazanavir or ritonavir: Decrease clarithromycin dose by 50%.,,201807111148,201807111147
OLACS,成人,Clcr,0,30.00,mL/min,mL/min,Avoid use. (KDIGO 2012 guideline),,201912091130,202303091002
OLACS,成人,Clcr,30.00,60.00,mL/min,mL/min,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury. (KDIGO 2012 guideline),,201912091130,202303091002
OLAMC,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全病患降低維持劑量仍是有效的,,201804160440,201804160440
OLAMS,成人,Clcr,0,49.99,mL/min,mL/min,腎功能損害患者的研究尚未充份，因此不建議使用於這類患者,,,202303091000
OLAT,成人,Clcr,0,49.90,mL/min,mL/min,CrCl <50 mL/minute: Initial: 20 mg daily; maximum: 80 mg/day,,201803291528,202303090959
OLEE,成人,Clcr,0,30.00,mL/min,mL/min,Severe impairment: CrCl <30 mL/minute: Use with caution.,,201809161629,202303091001
OLEEV,成人,Clcr,0,19.99,mL/min,mL/min,Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment,,201907181504,201804301513
OLEEV,成人,Clcr,20.00,39.99,mL/min,mL/min,Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.,,201907181504,202303091001
OLEEV,成人,Clcr,40.00,59.99,mL/min,mL/min,Maximum recommended dose: 600 mg.,,201907181504,201804301513
OLENV,成人,Clcr,0,29.99,mL/min,mL/min,分化型甲狀腺癌：14mg QD PO 腎細胞癌：10mg QD PO 子宮內膜癌：10mg QD PO 重度腎功能不全之HCC病人無使用建議劑量,仿單 20230728,202307281754,202307281759
OLEUK,成人,Clcr,0,0,mL/min,mL/min,有腎功能損傷跡象的病患須小心地監測，因易於罹患與氮血症有關之附加性骨髓抑制,,201804261552,202303091001
OLEX3,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者建議從最低劑量開始使用,,201804150021,201804150021
OLEXA,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者應謹慎使用,,201804150033,201804150033
OLINI,成人,Clcr,0,30.00,mL/min,mL/min,劑量調高至每天20mg者應小心謹慎，使用時應加注意,,201804130719,201804130719
OLIPS,成人,Clcr,0,29.99,mL/min,mL/min,嚴重慢性腎臟疾病，不可使用fenofibrate。,20230822 仿單,202308221536,201804130730
OLIPS,成人,Clcr,30.00,60.00,mL/min,mL/min,中度慢性腎臟疾病，若有較低劑量的藥品，每日一次每次使用一顆100 mg膠囊或67 mg微粒化膠囊。若無較低劑量的藥品，則不建議使用fenofibrate。,20230822 仿單,202308221535,202308221537
OLIVA,成人,Clcr,15.00,29.00,mL/min,mL/min,起始劑量:1 mg orally once daily (包含透析病人),最高劑量:2 mg/day,201804130734,201804130734
OLIVA,成人,Clcr,30.00,59.00,mL/min,mL/min,起始劑量:1 mg orally once daily,最高劑量:2 mg/day,201804130733,202303091000
OLIX,成人,Clcr,0,14.90,mL/min,mL/min,Use is not recommended,,201804191153,202303091000
OLIX,成人,Clcr,15.00,50.00,mL/min,mL/min,30 mg once daily.,,201804191153,202303091001
OLON,兒童,Clcr,60.00,0,mL/min,mL/min,No dosage adjustment of etodolac is necessary in patients with mild-to-moderate renal failure. However， etodolac should be used with caution because it may cause cumulative effects on renal function especially in patients with pre-existing mild-to-moderate renal dysfunction,Micromedex 2020/11/27,202011271213,202011271213
OLONS,成人,Clcr,30.00,0,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer's labeling,,201908051522,202303091000
OLOX,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustment provided in manufacturer's labeling.,,201804191056,202303091000
OLYR,成人,Clcr,0,14.99,mL/min,mL/min,Adults: 25 to 75 mg once daily,Micromedex 20200803,202008031440,202008031441
OLYR,成人,Clcr,0,15.00,mL/min,mL/min,原使用600mg BID or TID: 75mg QD. 原使用450mg BID or TID: 50-75mg QD. 原使用300mg BID or TID: 25-50mg QD. 原使用150mg BID or TID: 25mg QD.,仿單,202008031433,202008031432
OLYR,成人,Clcr,14.99,30.00,mL/min,mL/min,Adults: 25 to 150 mg/day given once daily or in 2 divided doses,Micromedex 20200803,202008031439,202008031440
OLYR,成人,Clcr,15.00,30.00,mL/min,mL/min,原使用600mg BID or TID: 150mg QD or BID. 原使用450mg BID or TID: 100-150mg QD or BID. 原使用300mg BID or TID: 75mg QD or BID. 原使用150mg BID or TID: 25-50mg QD or BID.,仿單,201804160453,202008031432
OLYR,成人,Clcr,29.99,60.00,mL/min,mL/min,Adults: 75 to 300 mg/day in 2 to 3 divided doses,Micromedex 20200803,202008031438,202008031438
OLYR,成人,Clcr,30.00,60.00,mL/min,mL/min,原使用600mg BID or TID: 300mg BID or TID. 原使用450mg BID or TID: 225mg BID or TID. 原使用300mg BID or TID: 150mg BID or TID. 原使用150mg BID or TID: 75mg BID or TID.,仿單,201804160452,202008031431
OLYR,成人,Clcr,60.00,99.99,mL/min,mL/min,Adults: No adjustment required,Micromedex 20200803,202008031437,202008031437
OMEDA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustment provided in manufacturer's labeling.,,201804191053,202303091001
OMELE,成人,Clcr,0,10.00,mL/min,mL/min,應依病患個別狀況調整劑量,,201804120050,201804120050
OMEPR,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231424,201804231424
OMETH,成人,Clcr,0,10.00,mL/min,mL/min,Increase dosage interval to 12 to 24 hours,,201804130700,201804130700
OMETH,成人,Clcr,10.00,50.00,mL/min,mL/min,Increase dosage interval to 8 to 12 hours,,201804130700,201804130659
OMETH,成人,Clcr,50.00,0,mL/min,mL/min,Increase dosage interval to 8 hours,,201804130659,201804130659
OMEV4,成人,Clcr,0,15.00,mL/min,mL/min,起始劑量:10 mg orally once daily,,201804130736,201804130736
OMEZA,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,禁忌使用,未有特別針對肝或腎功能不全所做的試驗,201904021508,201904021509
OMIDO,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者需注意投與劑量，謹慎使用，建議起始劑量 2.5 mg,,201804130647,201804130701
OMIN6,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,,201804242350,201804242350
OMIRA,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804160531,201804160531
OMIRA,成人,Clcr,30.00,50.00,mL/min,mL/min,開始時必須每隔一天服用一次MIRAPEX PR。須謹慎用藥，並仔細評估治療反應及耐受性，才可於一週後調高每日劑量，並進一步以每次0.375 mg的增幅將劑量調至最高一天2.25 mg。,劑量調整頻率不可多於一週一次。,201804160530,202303090959
OMIRT,成人,Clcr,0,10.00,mL/min,mL/min,口服單劑15毫克mirtazapine後，相較於正常受試者，腎臟重度受損(肌酸酐清除率 <10 ml/min)，mirtazapine的清除率約降低50%。Mirtazapine的平均血中濃度增加115%。這類患者給予mirtazapine 時須留意。,仿單,201806261029,201806261030
OMIRT,成人,Clcr,10.00,40.00,mL/min,mL/min,口服單劑15毫克mirtazapine後，相較於正常受試者，腎臟中度受損(肌酸酐清除率 >10 ml/min，<40 ml/min)，mirtazapine的清除率約降低30%。Mirtazapine的平均血中濃度增加55%。這類患者給予mirtazapine 時須留意。,仿單,201806261026,201806261030
OMIRT3,成人,eGFR,0,29.90,mL/min/1.73m2,mL/min/1.73m2,Initial: 7.5-15 mg HS; titrate slowly with close monitoring for adverse effects.,Lexidrug 20240617,202406171502,
OMIRT3,成人,eGFR,0,1.00,mL/min/1.73m2,mL/min/1.73m2,Hemodialysis， intermittent (thrice weekly)， Peritoneal dialysis， CRRT， PIRRT: Initiate at 7.5-15 mg once daily and titrate slowly with close monitoring for adverse effects.,Lexidrug 20240617,202406171504,
OMIRT3,成人,eGFR,30.00,120.00,mL/min/1.73m2,mL/min/1.73m2,No dosage adjustment necessary.,Lexidrug 20240617,202406171502,
OMOBI,成人,Clcr,0,15.00,mL/min,mL/min,不建議使用,,201804141621,201804141621
OMON,成人,Clcr,0,10.00,mL/min,mL/min,(含血液透析患者)不建議使用,,,202303090959
OMOR1,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50% or consider alternative opioid analgesics,,201804141510,201804141510
OMOR1,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 25%,,201804141509,202303091001
OMORC,成人,Clcr,0,15.00,mL/min,mL/min,CrCl below 15 mL/min: Use not recommended.,Micromedex 20210514,202105140917,202105140924
OMORC,成人,Clcr,15.00,30.00,mL/min,mL/min,CrCl 15 to 30 mL/min: Use standard dosing regimen， but decrease the amount of each dose by 50%,Micromedex 20210514,202105140916,202105140924
OMORC,成人,Clcr,30.00,999.00,mL/min,mL/min,CrCl greater than 30 mL/min: No adjustment necessary; use standard dosing regimen.,Micromedex 20210514,202105140916,202105140924
OMTX,成人,Clcr,0,9.90,mL/min,mL/min,禁止使用,仿單 20240528,202405281655,202405281655
OMTX,成人,Clcr,10.00,29.90,mL/min,mL/min,避免使用，若無合適替代療法必須使用，降低50%劑量,仿單 20240528,202405281655,202405281656
OMTX,成人,Clcr,30.00,59.90,mL/min,mL/min,降低50%之治療劑量，避免高劑量療法,仿單 20240528,201804261554,202405281656
ONAT,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804120107,202303091000
ONEO,成人,Clcr,0,9.00,mL/min,mL/min,increase interval to every 18-24 hours,,,202303090959
ONEO,成人,Clcr,10.00,49.00,mL/min,mL/min,increase interval to every 12-18 hours,,,202303090959
ONEO,成人,Clcr,50.00,120.00,mL/min,mL/min,increase interval to every 6 hours,,,202303090958
ONEOT,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者不建議使用,,201804191608,201804191608
ONES,成人,Clcr,0,14.99,mL/min,mL/min,ESRD (CrCl <15 mL/minute or requiring hemodialysis): 6.25 mg once daily; administered without regard to timing of hemodialysis. Use of alogliptin has not been studied in patients undergoing peritoneal dialysis.,,201809101542,201809131656
ONES,成人,Clcr,15.00,29.99,mL/min,mL/min,6.25 mg once daily,,201809101541,202303091002
ONES,成人,Clcr,30.00,59.99,mL/min,mL/min,12.5 mg once daily.,,201809101541,202303091001
ONEU,成人,Clcr,15.00,29.00,mL/min,mL/min,200 to 700 mg/day given once daily,,201804160456,201804160458
ONEU,成人,Clcr,30.00,59.00,mL/min,mL/min,400 to 1400 mg/day given in 2 divided doses,,201804160456,201804160458
ONEU,成人,Clcr,60.00,0,mL/min,mL/min,900 to 3600 mg/day given in 3 divided doses,,201804160455,201804160457
ONEU1,成人,Clcr,0,14.99,mL/min,mL/min,150-300 mg/day (若為150 mg/day應以300 mg 隔天服用一次的方式給予),仿單 20240103,202401031608,202401031608
ONEU1,成人,Clcr,15.00,29.99,mL/min,mL/min,150-600 mg/day (若為150 mg/day應以300 mg 隔天服用一次的方式給予),仿單 20240103,202401031605,202401031607
ONEU1,成人,Clcr,30.00,49.99,mL/min,mL/min,300-900 mg/day,仿單 20240103,202401031607,202401031607
ONEU1,成人,Clcr,50.00,79.99,mL/min,mL/min,600-1800 mg/day,仿單 20240103,202401031605,202401031605
ONUB,成人,eGFR,0.01,15.00,mL/min/1.73m2,mL/min/1.73m2,No dosage adjustments provided in the manufacturer's labeling (has not been studied).,Lexidrug 20240326,202403260955,202403260956
ONUB,成人,eGFR,15.01,29.99,mL/min/1.73m2,mL/min/1.73m2,Not receiving hemodialysis: Reduce dosage to 300mg BID,Lexidrug 20240326,202403260954,202403260957
ONUM,成人,Clcr,0,1.00,mL/min,mL/min,腎功能對 levodopa/carbidopa 的廓清影響有限。Numient相關研究尚未針對使用於腎功能不全患者進行探究。建議謹慎投予重度腎功能不全患者。,仿單 20231222,202312221337,202312221337
ONURT,成人,Clcr,0,14.99,mL/min,mL/min,Avoid use. Dialysis: Avoid use.,Micromedex 20241017,202410171604,202410171606
ONUX,成人,Clcr,0,20.00,mL/min,mL/min,禁用,,201804160605,201804160606
ONUX,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,,201804160606,201804160606
ONUX,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,,201804160605,202303091001
ONUX,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,,201804160604,202303091001
OOKP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病患應考慮給予較低的起始劑量(5毫克),,201804142359,201804142359
OPAN,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 hours,,201804142325,201804142325
OPAN,成人,eGFR,10.00,50.00,mL/min,mL/min,increase dosing interval to every 6 hours,,201804142324,201804142324
OPAN,成人,eGFR,50.00,0,mL/min,mL/min,increase dosing interval to every 4 hours,,201804142323,201804142324
OPAN,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,give usual weight or age-based dose,,201804142326,201804142326
OPAX,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議重度腎功能不全（基於 CKD-EPI 公式，eGFR < 30 mL/min）病人使用本品。,仿單,202205031047,202301041107
OPAX,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,中度腎功能不全(eGFR:30-60 mL/min)病人，劑量降低至150mg Nirmatrelvir + 100mg ritonavir，每日兩次，持續5天。處方應詳細說明Paxlovid內每種活性成分的劑量。醫師/藥師應就腎功能不全病人的給藥說明提供建議。,仿單,202205031046,202205031051
OPAXS,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議重度腎功能不全（基於 CKD-EPI 公式，eGFR < 30 mL/min）病人使用本品。,仿單,202301041106,202301041107
OPAXS,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,中度腎功能不全(eGFR:30-60 mL/min)病人，劑量降低至150mg Nirmatrelvir + 100mg ritonavir，每日兩次，持續5天。處方應詳細說明Paxlovid內每種活性成分的劑量。醫師/藥師應就腎功能不全病人的給藥說明提供建議。,仿單,202301041107,202301041107
OPAXS1,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Use not recommended.,Micromedex 20240326,202403261535,202403261535
OPAXS1,成人,eGFR,30.00,59.99,mL/min/1.73m2,mL/min/1.73m2,Nirmatrelvir 150 mg + ritonavir 100 mg BID for 5 days. Removal of 1 nirmatrelvir tablet from the morning and evening doses of all blister packs is required prior to dispensing.,Micromedex 20240326,202403261534,202403261535
OPKM,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,201804160539,201804160539
OPKM,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,201804160538,202303091001
OPKM,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,201804160538,202303090959
OPON,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.,KDIGO 2012,201804141552,202408221630
OPON,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.,KDIGO 2012,201912091232,202408221631
OPR150,成人,Clcr,0,29.90,mL/min,mL/min,Nonvalvular atrial fibrillation:There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,,201804191158,202303090959
OPR150,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:75 mg twice daily,,201804191156,202303091000
OPRAD,成人,Clcr,0,15.00,mL/min,mL/min,Nonvalvular atrial fibrillation:There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,,201804191200,201910241136
OPRAD,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:75 mg twice daily,,201804191200,202303091000
OPRI,成人,Clcr,0,0,mL/min,mL/min,輕度至中度腎功能不全的病人應謹慎使用,重度腎功能不全病人不建議使用Priligy,201804212347,201804212347
OPRIP,成人,Clcr,0,40.00,mL/min,mL/min,Initiate at 50% of usual dosage  最大劑量為單一劑量每公斤體重0.2毫克(0.2mg/kg/dose),每日總劑量不可超過每公斤體重0.5毫克,201804141434,201804141434
OPRM,成人,Clcr,0,0,mL/min,mL/min,ESRD (including hemodialysis or continuous ambulatory peritoneal dialysis)  Diabetic Gastroparesis: 5 mg orally twice daily; Maximum 10 mg/day. Gastroesophageal reflux disease: 5 mg orally 30 minutes before each meal and at bedtime OR 10 mg twice daily; Maximum 20 mg/day.,Micromedex 20221206,202212061033,202212061036
OPRM,成人,Clcr,60.00,0,mL/min,mL/min,Diabetic Gastroparesis: 5 mg orally 30 minutes before each meal and at bedtime; Maximum: 20 mg/day. Gastroesophageal reflux disease: 5 mg orally 30 minutes before each meal and at bedtime OR 10 mg three times daily; Maximum: 30 mg/day.,Micromedex 20221206,202212061029,202303091000
OPYRZ,成人,Clcr,0,29.99,mL/min,mL/min,25 to 35 mg/kg/dose 3 times per week administered after dialysis.,,202003151009,202303091001
OPZA5,成人,Clcr,0,30.00,mL/min,mL/min,25 to 35 mg/kg orally 3 times a week,3gm/day,,202303090959
OPZAT,成人,Clcr,0,29.99,mL/min,mL/min,25 to 35 mg/kg/dose 3 times per week administered after dialysis.,,201812031139,202303090959
OQTE,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,禁用於eGFR低於45mL/min/1.73m2的病人,仿單,202112201105,202303090959
OQTE,成人,eGFR,0.01,45.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， moderate to severe (estimated GFR less than 45 mL/min/1.73 m(2)): Use is contraindicated,Micromedex 20211220,202112201106,202303091000
OQUEP,成人,Clcr,0,0,mL/min,mL/min,Quetiapine XR 用於腎功能不全病人的臨床經驗有限,仿單,202007011201,202303091001
ORAD,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙，腎功能低下及addison氏症應謹慎服用,,201804261513,201804261513
ORANC,成人,Clcr,0,30.00,mL/min,mL/min,部份重度腎功能不全病人服用Ranolazine 後，發生急性腎衰竭。若發生急性腎衰竭(如，血漿肌酸酐升高且伴隨血液尿素氮升高)，請停止服用Ranolazine 並接受適當治療。,仿單,202101041850,202101050822
ORANC,成人,Clcr,30.01,60.00,mL/min,mL/min,中重度腎功能不全病人，在開始使用Ranolazine時及服用Ranolazine期間，需定期監測血漿肌酸酐及血液尿素氮是否升高。,仿單,202101041851,202101050822
OREOS,成人,Clcr,29.99,0,mL/min,mL/min,CrCl less than 30 mL/min， use not recommended,Micromedex 20201015,202010151008,202010151006
OREOS,成人,Clcr,30.00,0,mL/min,mL/min,重度腎功能障礙（肌胺酸酐廓清率＜30ml/min）之患者不建議使用,仿單,202010150950,202010151006
OREX,成人,Clcr,60.00,0,mL/min,mL/min,MAX 2 mg once daily (major depressive disorder) or MAX 3 mg once daily (schizophrenia),Micromedex 20210330,202103301120,202103301121
ORIB,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804150003,201804150003
ORIB,成人,Clcr,10.00,30.00,mL/min,mL/min,dosing should be reduced to a third of usual doses,,201804150003,202303091001
ORIB,成人,Clcr,30.00,60.00,mL/min,mL/min,A dose reduction of 50%,,201804150002,202303090959
ORIBA,成人,Clcr,0,29.99,mL/min,mL/min,decrease ribavirin to 200 mg ORALLY once daily and decrease peginterferon alfa-2a to 135 mcg SUBQ once weekly; do not attempt further decreases of ribavirin; if severe adverse reactions or laboratory abnormalities occur， discontinue ribavirin; if therapy is restarted and intolerance continues， discontinue regimen.,,,202303090958
ORIBA,成人,Clcr,30.00,50.00,mL/min,mL/min,decrease ribavirin to alternating daily doses of 200 mg and 400 mg ORALLY every other day,,,202303090958
ORIF3,成人,Clcr,0,10.00,mL/min,mL/min,50% of the normal daily dose,,,202303090959
ORIF3,成人,Clcr,10.00,50.00,mL/min,mL/min,50% to 100% of the normal dose,,,202303091001
ORIF5,成人,Clcr,0,0.99,mL/min,mL/min,chronic kidney disease or ESRD and HIV: peritoneal dialysis， 50% to 100% of the full dose， with an extra 50% to 100% of the full dose after peritoneal dialysis.,Micromedex 20210301,202103010859,202303091002
ORIF5,成人,Clcr,0,1.00,mL/min,mL/min,chronic kidney disease or ESRD and HIV: hemodialysis， 50% to 100% of the full dose with no supplement following hemodialysis.,Micromedex 20210301,202103010858,202303091000
ORIF5,成人,Clcr,0,50.00,mL/min,mL/min,chronic kidney disease or ESRD and HIV: CrCl 50 mL/min or less， 50% to 100% of the full dose,Micromedex 20210301,202103010857,202303091001
ORIF5,成人,Clcr,0.01,60.00,mL/min,mL/min,腎功能不全病人，不需要降低劑量。此外，腎小球過濾速率(GFR)降低及無尿症的病人，並不意味其Rifampin的血漿濃度亦會改變。,仿單 20240909,202409091404,202303091002
ORIFA,成人,Clcr,0,30.00,mL/min,mL/min,Pyrazinamide: 25 to 35 mg/kg orally 3 times a week,,201803230959,201803231006
ORIFA,成人,Clcr,0,9.99,mL/min,mL/min,Rifampin: 50% of the full dose,,201803230958,201803231006
ORIFA,成人,Clcr,10.00,50.00,mL/min,mL/min,Rifampin: 50% to 100% of the full dose,,201803230958,201803231006
ORIFI,成人,Clcr,0,9.99,mL/min,mL/min,Rifampin: 50% of the full dose,,201803231003,201803231004
ORIFI,成人,Clcr,0,30.00,mL/min,mL/min,Pyrazinamide: 25 to 35 mg/kg orally 3 times a week,,201803231004,201803231004
ORIFI,成人,Clcr,10.00,50.00,mL/min,mL/min,Rifampin: 50% to 100% of the full dose,,201803231003,201803231005
ORISD,成人,Clcr,0,30.00,mL/min,mL/min,Initial， 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day， with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,,201804142345,201804142345
ORYB,成人,Clcr,30.00,0.01,mL/min,mL/min,不建議用於末期腎病的病人,仿單 20230404,202304041351,202304041351
ORYB14,成人,Clcr,30.00,0.01,mL/min,mL/min,不建議用於末期腎病的病人,仿單 20230404,202410070934,202410070934
OSAB,成人,Clcr,10.00,30.00,mL/min,mL/min,Decrease dose by 75%,,201804160500,201804160500
OSAB,成人,Clcr,30.00,50.00,mL/min,mL/min,Decrease dose by 50%,,201804160500,202303091001
OSAB,成人,Clcr,50.00,80.00,mL/min,mL/min,Decrease dose by 25%,,201804160500,202303091001
OSAM,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804121434,201804121434
OSAN1,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,腎病症候群 為誘導緩解作用，建議劑量為成人每日每公斤體重 5 毫克。起始劑量不應超過每日每公斤體重2.5 毫克。 類風濕性關節炎 前6 週之治療的建議劑量為每日每公斤體重 3 毫克，分成兩次。不應該超過每公斤體重5 毫克。要達到最大的療效、新 體睦療程需要持續長達12 週。新體睦起始劑量為每日每公斤體重2.5 毫克、分成兩次給藥，並依照病患耐受性允許來增加治療劑量。 乾癬 建議起始劑量為每日每公斤體重2.5 毫克分成兩次。不應超過每公斤體重5 毫克。,,201804231705,202303091001
OSEB,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:600 mg ORALLY every 96 hours，give after hemodialysis,,,202303090958
OSEB,成人,Clcr,0,29.99,mL/min,mL/min,600 mg ORALLY every 72 hours,,,202303090958
OSEB,成人,Clcr,30.00,49.99,mL/min,mL/min,600 mg ORALLY every 48 hours,,,202303090958
OSEF,成人,Clcr,0,5.00,mL/min,mL/min,single dose of 400 mg or 9 mg/kg at the end of each hemodialysis session,血液透析病人,,202303090958
OSEF,成人,Clcr,5.00,29.00,mL/min,mL/min,100 mg every 24 hours or 2.25 mg/kg every 24 hours,,,202303090958
OSEF,成人,Clcr,30.00,49.00,mL/min,mL/min,200 mg every 24 hours or 4.5 mg/kg every 24 hours,,,202303090958
OSEF,成人,Clcr,50.00,120.00,mL/min,mL/min,無須調整劑量,,,202303090958
OSELA,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804141554,201804141555
OSER1,成人,Clcr,0,30.00,mL/min,mL/min,建議將劑量限制在最低範圍,,201804150040,201804150042
OSERM,成人,Clcr,10.00,25.00,mL/min,mL/min,重度腎功能不全的病患，其藥物排除下降，應注意調整劑量,,201804130657,201804130657
OSERO,成人,Clcr,29.99,0.01,mL/min,mL/min,Severe impariement: Begin with 10 mg QD in the morning. May increase dosage as clinically needed in 10 mg/day increments at intervals of at least 1 week to a maximum dosage of 40 mg/day.,Micromedex 20230329,202303291635,202303291637
OSERO,成人,Clcr,30.00,0,mL/min,mL/min,20 mg/day. If an increase is necessary， limit dose to the lower end of the dosage range.,仿單 20230329,202303291411,202303291411
OSPI,成人,eGFR,30.00,49.00,mL/min/1.73m2,mL/min/1.73m2,起始劑量:12.5 mg orally once a day,維持劑量: 12.5mg~25 mg once a day after 4 weeks for potassium 5 mEq/L or less,201804120120,201804120121
OSPI,成人,eGFR,50.00,0,mL/min/1.73m2,mL/min/1.73m2,起始劑量:12.5 mg to 25 mg orally once a day,維持劑量:25 mg once or twice a day after 4 weeks for potassium 5 mEq/L or less,201804120117,201804120120
OSPL,成人,Clcr,9.99,0,mL/min,mL/min,34% of normal dose,Micromedex 20230308,202303081939,202303081939
OSPL,成人,Clcr,29.99,10.00,mL/min,mL/min,50% of normal dose,Micromedex 20230308,202303081939,202303081939
OSPL,成人,Clcr,60.00,30.00,mL/min,mL/min,70% of normal dose,Micromedex 20230308,202303081938,202303081939
OSUL,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.(KDIGO 2012 guidelines),,201912091238,201912091238
OSUL,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.(KDIGO 2012 guidelines),,201912091237,201912091237
OSUL,成人,Clcr,0,0,mL/min,mL/min,明顯腎功能不全之病患，可減少每日劑量，避免藥物積蓄,,201804141600,202303091001
OSUN,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:無須調整劑量,,,202303090958
OSUN,成人,Clcr,0,29.99,mL/min,mL/min,每日一次100mg,,,202303090958
OSUT,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,ESRD on hemodialysis: No initial adjustment required; subsequent dosage increases (up to twofold) may be required due to reduced (47%) exposure.,,201804301505,202303090959
OSYN1,成人,Clcr,0,20.00,mL/min,mL/min,禁用,仿單,202012021554,201804160606
OSYN1,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,仿單,202012021554,201804160606
OSYN1,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,仿單,202012021553,202303090959
OSYN1,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,仿單,202012021553,202303091001
OSYNG,成人,Clcr,0,20.00,mL/min,mL/min,Use is contraindicated.,,202001081115,202303091000
OSYNG,成人,Clcr,20.00,30.00,mL/min,mL/min,Decrease to 1/6 of the normal daily dose administered once daily.,,202001081116,202303091000
OSYNG,成人,Clcr,30.00,49.00,mL/min,mL/min,Initial and maximum dose: Decrease to 1/3 of the normal daily dose administered in 2 divided doses.,,202001081116,202303091002
OSYNG,成人,Clcr,50.00,79.00,mL/min,mL/min,Initial and maximum dose: Decrease to 2/3 of the normal daily dose administered in 2 to 3 divided doses.,,202001081116,202303091001
OTAI,成人,Clcr,0,60.00,mL/min,mL/min,腎功能不全：中度至重度腎功能不全病人及末期腎臟疾病（ESRD）病人不建議使用本藥品。,仿單,202301111655,202303090959
OTAI,成人,Clcr,60.00,90.00,mL/min,mL/min,輕度腎功能不全病人（肌酸酐清除率【CLcr】60~90 mL/min）不須調整用藥劑量。,仿單,202301111655,202301111656
OTAM7,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:30 mg orally immediately， then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days from the time of the initial dose,,,202303090958
OTAM7,成人,Clcr,10.00,29.99,mL/min,mL/min,30 mg orally once daily for 5 days,,,202303090958
OTAM7,成人,Clcr,30.00,59.99,mL/min,mL/min,30 mg orally twice daily for 5 days,,,202303090958
OTAMI,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:30 mg orally immediately， then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days from the time of the initial dose,,,202303090958
OTAMI,成人,Clcr,10.00,29.99,mL/min,mL/min,30 mg orally once daily for 5 days,,,202303090958
OTAMI,成人,Clcr,30.00,59.99,mL/min,mL/min,30 mg orally twice daily for 5 days,,,202303090958
OTAN,成人,Clcr,0,30.00,mL/min,mL/min,建議將常用劑量減半或將投與間隔延長,,201804121553,201804121553
OTENO,成人,Clcr,0,15.00,mL/min,mL/min,最高劑量:25 mg ORALLY once daily,,201804121455,201804121455
OTENO,成人,Clcr,15.00,35.00,mL/min,mL/min,最高劑量:50 mg ORALLY once daily,,201804121454,202303091001
OTET2,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer recommended dose based on indication every 24 hours.,,201812171106,202303091001
OTET2,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer recommended dose based on indication every 12 to 24 hours.,,201812171105,202303091000
OTET3,成人,Clcr,0,9.99,mL/min,mL/min,Avoid use; if necessary， 250-500mg q24h (CCR<10 & Hemodialysis & CAPD),Sanford Guide 20230712,202307121544,202307121547
OTET3,成人,Clcr,10.00,50.00,mL/min,mL/min,250-500mg q12-24h,Sanford Guide 20230712,202307121543,
OTET3,成人,Clcr,51.00,90.00,mL/min,mL/min,250-500mg q8–12h,Sanford Guide 20230712,202307121542,202307121543
OTET3,成人,Clcr,91.00,999.00,mL/min,mL/min,250–500mg q6h,Sanford Guide 20230712,202307121546,202307121546
OTON,成人,Clcr,0,3.00,mL/min,mL/min,100 mg orally at extended intervals,,201804142316,201804142316
OTON,成人,Clcr,3.00,10.00,mL/min,mL/min,Do not exceed 100 mg orally daily,,201804142315,202303091000
OTON,成人,Clcr,10.00,20.00,mL/min,mL/min,200 mg orally daily,,201804142315,202303091000
OTOP5,成人,Clcr,0,70.00,mL/min,mL/min,Use 50% of the usual adult dosage,,201804160505,201804160505
OTRA2,成人,Scr,1.36,2.83,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose twice daily,,201804231440,202303090959
OTRA2,成人,Scr,2.83,5.66,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose once daily,,201804231440,202303091001
OTRA2,成人,Scr,5.67,99.00,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose every 48 hours or 5 mg/kg/dose once daily,,201804231441,202303090959
OTRCT,成人,Clcr,0,30.00,mL/min,mL/min,增加本品的給藥間隔，每12小時不要超過兩錠。,仿單,202201111150,202201111151
OTRCT,成人,Clcr,0,30.01,mL/min,mL/min,Do not exceed 2 tablets every 12 hours,Micromedex 20220111,202201111149,202201111150
OTRIL,成人,Clcr,0,30.00,mL/min,mL/min,治療劑量應為一般起始劑量應為一半(每天300mg)，再逐漸增加劑量以達到理想的臨床效果,,201804160425,201804160425
OTRO,成人,Clcr,0,70.00,mL/min,mL/min,Use 50% of the usual adult dosage,[Micromedex 20200703],202007051227,202007051230
OTRO,成人,Clcr,0,69.99,mL/min,mL/min,在腎功能不全（肌酸酐清除率低於 70 mL/min/1.73 m2）患者中，建議使用一般成人用劑量的一半。,[仿單],202007011643,202007051229
OTS1,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙脂患者應警慎投與 (因5-FU代謝J抑制劑gimeracil於尿液中之排除減少，使5-FU血中濃度上升),嚴重腎功能障礙患者不建議使用,201804261602,201804261605
OUFR,成人,Clcr,0,30.00,mL/min,mL/min,500 to 1000 mg orally every 24 hours (extended-release tablet),,201804160415,201804160415
OUFR,成人,Clcr,30.00,50.00,mL/min,mL/min,500 to 1500 mg orally every 24 hours (extended-release tablet),,201804160415,202303090959
OUFR,成人,Clcr,50.00,80.00,mL/min,mL/min,1000 to 2000 mg orally every 24 hours (extended-release tablet),,201804160415,202303091001
OUFU,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之患者應警慎投與(副作用可能加重),,201804261608,201903031533
OULT,成人,Clcr,0,30.00,mL/min,mL/min,建議增加給藥間隔，每12小時不要超過兩錠,,201804141535,202303091000
OURA,成人,Clcr,0,30.00,mL/min,mL/min,20 mg orally once daily at bedtime,,201804212351,201804212351
OURI2,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能障礙者不建議使用,,201804212324,201804212324
OURI2,成人,Clcr,30.00,50.00,mL/min,mL/min,建議以低劑量 2 mg 一天兩次 作為治療的開始劑量,,201804212321,202303091001
OURI2,成人,Clcr,50.00,80.00,mL/min,mL/min,輕度腎功能障礙者無須調整劑量,,201804212322,201804212322
OURI8,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能障礙者不建議使用,,201904080914,202303091002
OURI8,成人,eGFR,30.00,50.00,mL/min/1.73m2,mL/min/1.73m2,建議以低劑量 2 mg 一天兩次 作為治療的開始劑量,,201904080913,202303091002
OURI8,成人,eGFR,50.00,80.00,mL/min/1.73m2,mL/min/1.73m2,輕度腎功能障礙者無須調整劑量,,201904080913,202303091000
OUROD,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,do not use if GFR less than 50 mL/min,Micromedex 20210913,202109131600,202109131609
OUROD,成人,eGFR,50.00,99.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 to 16 hours.,Micromedex 20210913,202109131600,202109131610
OUROP,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use,Micromedex 20200703,201804212354,202007030854
OUROP,成人,eGFR,50.00,99.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 to 16 hours (Micromedex 20200703) 100 to 200 mg every 8 to 12 hours (UpToDate 20200703),,201804212353,202007030856
OVAL,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:帶狀皰疹:一天一次，每次1000mg;單純皰疹:一天一次，每次500mg;單純皰疹之預防:一天一次，每次250mg(免疫健全)，一天一次，每次500mg(免疫不全);須在血液透析完給藥,,,202303090958
OVAL,成人,Clcr,0,15.00,mL/min,mL/min,帶狀皰疹:一天一次，每次1000mg;單純皰疹:一天一次，每次500mg;單純皰疹之預防:一天一次，每次250mg(免疫健全)，一天一次，每次500mg(免疫不全),,,202303090958
OVAL,成人,Clcr,15.00,30.00,mL/min,mL/min,帶狀皰疹:一天兩次，每次1000mg;單純皰疹:一天兩次，每次500mg;單純皰疹之預防:一天兩次，每次250mg(免疫健全)，一天兩次，每次500mg(免疫不全),,,202303090958
OVEM,成人,Clcr,0,14.99,mL/min,mL/min,Use is not recommended.,,201812200952,202303091000
OVEP,成人,Clcr,0,14.99,mL/min,mL/min,Data not available; consider further dose reductions,,201804301530,202303091001
OVEP,成人,Clcr,15.00,50.00,mL/min,mL/min,Administer 75% of dose,,201804301530,202303091000
OVEP5,成人,Clcr,0,14.99,mL/min,mL/min,Data not available; consider further dose reductions,,201811051114,202303091002
OVEP5,成人,Clcr,15.00,50.00,mL/min,mL/min,Administer 75% of dose,,201811051115,201811051115
OVERZ,成人,Clcr,0,30.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).,[仿單]尚不清楚abemaciclib在重度腎臟功能不全(CLcr<30 mL/min)、末期腎臟疾病或接受透析病人的藥物動力學數據。,202206201121,202206201123
OVERZ0,成人,Clcr,0,30.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).,[仿單]尚不清楚abemaciclib在重度腎臟功能不全(CLcr<30 mL/min)、末期腎臟疾病或接受透析病人的藥物動力學數據。,202210241656,202206201123
OVES,成人,Clcr,0,30.00,mL/min,mL/min,建議劑量: 75 mg every 12 hours,,201804131628,201804131629
OVES,成人,Clcr,30.00,50.00,mL/min,mL/min,建議劑量: 150 mg every 24 hours,,201804131629,201804131630
OVESI,成人,Clcr,0,30.00,mL/min,mL/min,重度腎功能障礙者要謹慎給藥，每日不可多於 5 mg,洗腎患者不建議使用,201804212335,201804212337
OVESI,成人,Clcr,30.00,0,mL/min,mL/min,輕度及中度腎功能障礙者無須調整劑量,,201804212326,202303091000
OVGR1,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能不全患者的清除率會下降，因此應考慮使用25 mg的起始劑量。基於藥效及耐受性的考量，劑量可提高至50 mg或100 mg,,201804212234,202303091001
OVGRO,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能受損之患者的清除率會下降，因此應考慮使用25 mg的起始劑量。基於藥效及耐受的考量，劑量可提高至50 mg或100 mg,,201804212238,201804212238
OVIA1,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全者，應在醫護監督下給與,,201804191421,201804191421
OVIM,成人,Clcr,0,0,mL/min,mL/min,血液透析可有效清除血漿中的 Lacosamide。4 小時的血液透析治療後，應考慮補充最多 50%的劑量。,仿單,202008041021,202008031607
OVIM,成人,Clcr,0.01,0,mL/min,mL/min,Removed by hemodialysis; after 4-hour hemodialysis treatment， a supplemental dose of up to 50% should be considered.,UpToDate 20200803,202008041021,202008031611
OVIM,成人,Clcr,29.99,0,mL/min,mL/min,CrCl <30 mL/minute: Reduce dose to 75% of the maximum dose.,UpToDate 20200803,202008041021,202008031611
OVIM,成人,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,202008041022,202008031607
OVIM,成人,Clcr,60.00,29.99,mL/min,mL/min,CrCl >=30 mL/minute: No dosage adjustment necessary.,UpToDate 20200803,202008041022,202008031613
OVIR3,成人,Clcr,0,9.00,mL/min,mL/min,血液透析患者:300mg，給藥間隔每7天一次;或者進行透析的12小時後,,,202303090958
OVIR3,成人,Clcr,10.00,29.00,mL/min,mL/min,300mg，給藥間隔每72至96小時,,,202303090958
OVIR3,成人,Clcr,30.00,49.00,mL/min,mL/min,300mg，給藥間隔每48小時,,,202303090958
OVIR3,成人,Clcr,50.00,200.00,mL/min,mL/min,300mg，給藥間隔每24小時,,,202303090958
OVIS2,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全患者應謹慎使用,,201804242316,201804242316
OVOC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全的病人不建議使用福星定膜衣錠20mg每天2次。 Severe impairment (estimated GFR less than 30 mL/min): Avoid use,仿單、Micromedex (2022.10.05),202210051957,202210051959
OVYT,成人,Clcr,0,30.00,mL/min,mL/min,每日劑量超過 10/10mg 時，應小心使用,,201804130742,201804130742
OWELX,成人,eGFR,0,90.00,mL/min/1.73m2,mL/min/1.73m2,Consider reducing dose and/or frequency of dosing,,201804160332,202303091000
OWIT1,成人,Clcr,5.00,29.00,mL/min,mL/min,reduce dosage to 5 mg orally twice daily,Micromedex 2020.06.18,202006181220,202006181222
OWIT1,成人,Clcr,30.00,80.00,mL/min,mL/min,No adjustment necessary,Micromedex 2020.06.18,202006181221,202006181222
OXAR,成人,Clcr,0,15.00,mL/min,mL/min,Avoid use.,,201804191202,202303091000
OXAR,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal,仿單建議避免使用,201911251230,201911251234
OXAR,成人,Clcr,15.00,50.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal,,201804191203,202303091002
OXAR1,成人,Clcr,0,15.00,mL/min,mL/min,Avoid use.,,201804191211,202303091001
OXAR1,成人,Clcr,15.00,50.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal.,,201804191211,202303091001
OXAR25,成人,Clcr,14.99,0,mL/min,mL/min,CrCl less than 15 mL/min: Avoid use,Micromedex 20201217,202012171447,202012180919
OXAR25,成人,Clcr,15.00,0,mL/min,mL/min,CrCl < 15 mL/min 之病人禁止使用本品。,仿單,202012171445,202303091002
OXEL,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201803191621,202303091001
OXEL,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose to 75% of usual dose.,,201803191620,202303090959
OXELJ,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,Moderate to severe impairment: Reduce dose to 5 mg (immediate release) once daily. A supplemental dose after dialysis is not necessary in patients with severe impairment on dialysis.,,201804231707,202303090940
OXIG,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,避免使用,,202002101136,202002101136
OXIG,成人,eGFR,46.00,99.00,mL/min/1.73m2,mL/min/1.73m2,無須調整劑量,,201812261205,202002101136
OXOFL,成人,Clcr,0,30.00,mL/min,mL/min,目前尚無重度腎功能不全病患(CrCl <30 mL/min)投與本藥後的藥物動力學資料。,仿單 20230827,202001071010,202308271646
OXOFL,成人,Clcr,30.00,60.00,mL/min,mL/min,輕度或中度腎功能不全(CrCl >=30 mL/min)的患者，不需要調整劑量。,仿單 20230827,202001071011,202308271646
OXTA,成人,Clcr,0,30.00,mL/min,mL/min,Preexisting severe impairment (CrCl <30 mL/minute)， including end-stage renal disease (ESRD): There are no dosage adjustments provided in the manufacturer's labeling.,,201803301704,201803301705
OXTA,成人,Clcr,30.00,89.00,mL/min,mL/min,Preexisting mild-to-moderate impairment (CrCl 30 to 89 mL/minute): No initial dosage adjustment necessary.,,201803301706,201803301705
OXTA40,成人,Clcr,0,30.00,mL/min,mL/min,輕度或中度腎功能不全病人無須調整劑量。重度腎功能不全或末期腎病病人應小心使用。,仿單 20240708,202407081939,202407081941
OXYZ,成人,Clcr,0,14.90,mL/min,mL/min,Hemodialysis: Use is contraindicated.,仿單 20240528,201804231521,202405281554
OXYZ,成人,Clcr,15.00,29.90,mL/min,mL/min,5 mg every 3 days (不需要透析者),仿單 20240528,202405281554,202405281555
OXYZ,成人,Clcr,30.00,59.90,mL/min,mL/min,5 mg QOD,仿單 20240528,201804231520,202405281554
OYAZ,成人,Clcr,0,49.99,mL/min,mL/min,腎功能受損病人禁止使用YAZ,仿單 20240527,201804231351,202405271621
OZAN,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,禁用於有重度之肝功能不全病人或重度腎功能不全病人(GFR < 30 ml/min)，包括正在接受血液透析或腹膜透析的病人,仿單,201804121532,202007290924
OZAN,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,本藥曾在腹膜透析病人身上出現混濁的腹膜透析流出液。此混濁現象肇因於腹膜透析流出液中較高的三酸甘油酯濃度。機制不明，但此停用lercanidipne後迅速消失。有可能將混濁的腹膜透析流出液誤認為感染性腹膜炎，進而造成不必要的住院及經驗性抗生素施用。,仿單,202007290931,202007290934
OZCO,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191026,202303091001
OZES,成人,Clcr,0,10.00,mL/min,mL/min,起始劑量為2.5 mg/天,包含透析病人,201804121600,201804121601
OZES,成人,Clcr,10.00,30.00,mL/min,mL/min,起始劑量為2.5~5 mg/天,,201804121600,202303090959
OZES,成人,Clcr,31.00,80.00,mL/min,mL/min,起始劑量為5~10 mg/天,,201804121559,202303090959
OZIT,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,,202303090958
OZIT,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,,202303090958
OZON1,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者治療時應謹慎，可能需要減慢調高zonisamide劑量的速度,,201804160511,201804160511
OZUL,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Hemodialysis: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081158,202006081158
OZUL,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,severe， GFR 15 to 29 ， not receiving hemodialysis: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081159,202006081159
OZUL,成人,eGFR,30.00,59.00,mL/min/1.73m2,mL/min/1.73m2,moderate， GFR 30 to 59: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081200,202006081159
